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Abstract  
 Lung cancer exceeds all other diagnosed cancers in annual mortality, 
surpassing the top two annually diagnosed cancers breast and prostate, 
combined. The vast majority of diagnosed lung cancer cases are in current or 
former smokers, accounting for 85% of all cases. The number of diagnosed lung 
cancer cases continues to rise, addressing the need for novel intervention 
strategies. Despite current advances in chemoprevention for other less-fatal 
types of cancer, the only currently recognized chemopreventive strategy for lung 
cancer is smoking cessation. However, former smokers retain a 2.5-fold 
increased risk of developing lung cancer compared with never smokers, despite 
cessation efforts. About 40% of all newly diagnosed lung cancers occur in former 
smokers. As such, chemoprevention strategies for lung cancer are direly needed 
for the large and ever-growing high-risk population.  
Preclinical evaluation of existing therapies with established safety and 
efficacy profiles represents a fruitful opportunity to advance the field. 
Identification of ERβ expression has been found to be a lucrative method to 
identify lung cancers that confer poor survival and presents as a potential target 
for chemopreventive efforts. Preclinical evaluation of anti-estrogens in cell lines 
and mouse models of lung cancer shows great promise in advancing this class of 
drugs towards future clinical use in lung cancer prevention. Furthermore, anti-
estrogens such as fulvestrant, a complete ER antagonist, have shown anti-
tumorigenic activity in lung cancer and others such as tamoxifen have already 
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been successfully implemented in both primary and secondary breast cancer 
prevention modalities. Preclinical and clinical evidence underpinning the 
importance of managing ER signaling to control lung cancer initiation and 
progression, although efficacious, alludes to the potential for increased efficacy 
when used in combination with other agents. Pioglitazone, a synthetic 
peroxisome proliferator-activated receptor gamma (PPARγ) agonist belonging to 
the thiazolidinediones (TZDs) drug class has also been used in preclinical 
studies to mitigate lung tumorigenesis, progression, and metastasis after a 
retrospective analysis found that diabetics using TZDs experienced a 33% 
reduction in lung cancer incidence. PPARγ has also been implicated as a 
protective pathway in lung cancer initiation and progression in early phase 
clinical testing. Patients with improved histology scores demonstrated a link 
between an increased ER gene signature and positive-response to PPARγ 
activation, which conferred a chemopreventive effect in dysplasias with a 
persistent and progressive phenotype. This link presents a unique opportunity to 
utilize two known mechanisms that are efficacious in protecting against 
carcinogen-induced lung cancer initiation and progression. Cross-talk between 
PPARγ signaling and estrogen receptor (ER) signaling has also been previously 
reported in other cancer models.  
NNK is a principal carcinogen in cigarette smoke, and along with its ability to 
induce mutations in oncogenes, NNK can act as an inflammatory mediator of the 
tumor microenvironment (TME) by promoting macrophage infiltration into the 
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lungs. Furthermore, in previously reported NNK-models of lung cancer, immune 
cells thought to be macrophages that were positive for both aromatase and 
estradiol were localized to preneoplastic lesions. Taken together, macrophages 
are hypothesized to play a key role in regulation of the lung TME both through 
ER-dependent and independent mechanisms, and both ER and PPARγ 
pathways are also known to be functional.  
To develop a novel approach to prevent lung cancer, preclinical studies were 
developed to evaluate the therapeutic potential and chemopreventive capabilities 
of two FDA-approved agents, pioglitazone and fulvestrant, re-purposed in a lung 
cancer tumor microenvironment (TME) in vitro model and an NNK-induced 
adenocarcinoma chemoprevention in vivo model. To test pioglitazone and 
fulvestrant in a preclinical model simulating the lung TME, we selected a human 
NSCLC adenocarcinoma cell line with a similar KRAS mutational signature found 
in smoking-induced lung cancer and a human immortalized macrophage cell line. 
Additionally, we tested the effects of pioglitazone and fulvestrant in a murine 
primary cell culture model, utilizing mouse-derived adenocarcinoma cells 
immortalized from NNK-induced in vivo tumors and primary murine bone marrow-
derived macrophages (BMDMs). 
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Major Results 
Preliminary results from co-culture simulation of the TME in vitro using 
human macrophages and lung adenocarcinoma cells show pioglitazone and 
fulvestrant together can significantly suppress inflammatory modulators such as 
IL-1β, IL-10, Amphiregulin (AREG), and vascular endothelial growth factor 
(VEGF) compared to single treatments. Single treatments individually did not 
suppress tumor-promoting pathways IL-1β and AREG in co-culture models of the 
TME. Similar effects were observed in the murine primary cell model system of 
the TME. Comparison of resting-state M0 with tumor-associated macrophage 
(TAM) resembling M2 macrophages revealed that TAM-like macrophages are 
more sensitive to ER blockade. M2 compared with M0 macrophages displayed 
more than 2-fold increased expression of the estradiol-synthesizing enzyme 
aromatase. Furthermore, compensatory increased expression of aromatase seen 
with ER blockade through fulvestrant treatment was reduced by 50% with the 
addition of pioglitazone.  
In vivo use of combined pioglitazone and fulvestrant in both female pre 
and post-menopausal NNK-induced adenocarcinoma mouse models of former 
smoking showed significant treatment benefit. The pre-menopausal model 
conferred a reduction in lung tumor size by 48% compared with placebo (p= 
0.0265), compared to 23% for pioglitazone alone (p=0.5303) and 5% for 
fulvestrant alone (p=0.3591), and the post-menopausal model conferred a 
reduction in lung tumor size by 51% compared with placebo (p= 0.2601), 
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compared to 28% for pioglitazone alone (p=0.9867) and 13% for fulvestrant 
alone (p=0.2402). Inflammatory secreted protein analysis of the bronchio-alveolar 
lavage fluid (BALF) revealed maximum down-modulation of pro-tumorigenic 
growth and inflammatory mediators IL-10, IL-1β, EGF, AREG, and CCL2 with 
combination treatment compared to single treatments after a 3 week treatment 
duration. Furthermore, tissue analysis of the lungs after a 14 week treatment 
duration revealed a significant suppression of macrophage density with both 
single and combination treatments. The greatest suppression of macrophage 
burden was seen in combination treatment. Despite the robust macrophage 
chemotaxis suppression, early-stage immunomodulation, and anti-tumor effect of 
the combination, pioglitazone and fulvestrant combined treatment activated 
feedback loops by increasing expression of phosphorylated Akt in preneoplastic 
airways and MMP9-positive tumor-infiltrating immune cells after a 14 week 
treatment duration.  
 
Conclusion and Significance 
Assessment of pioglitazone and fulvestrant in combination reveals a 
strong anti-tumor effect conferred by a reduction in tumor incidence and size in 
NNK-exposed pre and post-menopausal mouse models of lung cancer after a 14 
week treatment duration. This result is likely to be mediated, in part, by the strong 
inflammatory regulation of tumor-supporting factors seen at early time points. A 
significant regulation of pathways known to directly support tumor formation and 
viii 
 
progression such as IL-10, IL-1β, AREG, VEGF, EGF, and MMP9 was observed, 
suggesting downstream crossover of pioglitazone and fulvestrant in hitting on 
these targets as well as other potential upstream regulators. Additionally, 
combination effectively suppressed a known monocyte chemotaxis factor CCL2. 
CCL2 regulation may be partially responsible for the robust decrease in 
macrophage burden with the combination in a late-stage assessment of the TME. 
Reduced macrophage density may also be a contributing factor in starving 
formed tumors of necessary growth factors and cytokines to invigorate further 
proliferation and survival.  
In vitro analysis of inflammatory mediators regulated in the lung TME 
confirms maximal regulation of the inflammatory landscape within the TME seen 
with combination. Individual treatments can confer possible activation of pro-
inflammatory and pro-proliferative compensatory signaling pathways such as IL-
1β and EGFR that are suppressed with combination treatment, again suggesting 
crossover of PPARγ and ER downstream targets implicated in tumor 
inflammation and growth signaling. Additionally, combination treatment can most 
effectively regulate heightened M0 and M2 macrophage aromatase expression 
and estradiol secretion, suggesting an enhanced effect on ER regulation with the 
addition of pioglitazone previously described in other models. Taken together, the 
combination of pioglitazone and fulvestrant are shown to re-educate the lung 
TME away from tumor-promoting estrogenic activity, primarily modulated by 
macrophages. 
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Thus, the strong combination effect of pioglitazone and fulvestrant on lung 
tumor growth and macrophage function, and the ability of the combination to 
suppress compensatory signaling pathways, supports the hypothesis of 
ER/PPARγ cross-talk in lung cancer and provides a rationale for further 
investigation of chemopreventive effects of this combination. 
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1. Introduction 
1.1 Lung Cancer Prevalence and Epidemiology 
 Lung cancer stands as the leading cause of death in both men and women 
in the United States with an estimated toll of 154,050 deaths in 2018 making it 
25.3% of all cancer-related deaths [1]. Lung cancer has remained the number 
one cause of cancer-related death in men since the 1950’s, and in 1987, it 
became the number one cancer killer in women, surpassing breast cancer [2]. 
Despite ongoing research efforts, lung cancer 5-year survival rates remain 
staggering low at 18.6% assessed by the National Cancer Institute’s (NCI) 
Survival, Epidemiology, and End Results (SEER) data program in 2018. 
Furthermore, lung cancer accounts for 13.5% of all new cancer cases [2]. Taken 
together, this data indicates the need for improved treatment and prevention 
strategies. 
According to a statistical report published in 2018, lung cancer rates 
closely correlate with historical differences in smoking initiation and cessation as 
well as prevalence of smoking in certain generational cohorts [3]. According to 
the Surgeon General’s report on the consequence of smoking, adult per capita 
cigarette consumption rose to all-time high between the years of 1940 and 1980 
[4]. At its peak, per capita cigarettes smoked annually topped 4,000 which could, 
in part, account for the plethora of newly diagnosed cases but does not address 
the aggressiveness of the disease underlying survival rates and the prevalence 
in non-smoking populations. In 1964, 40% of all Americans were active smokers, 
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and when assessed by sex, 53% of men and about 33% of women were active 
smokers [4]. In 2018, it was reported that approximately 20% of lung cancer 
related-deaths were in never-smoker cohorts totaling roughly 30,000 people [5].  
To date, smoking is identified as the number one cause of lung cancer 
fatality with approximately 80% of all lung cancer deaths attributable to a history 
of smoking [6]. In addition to the risks associated with traditional cigarette smoke, 
there is also research in risks associated with other types of tobacco. Cigar and 
pipe smoke increases cancer risk 5.1 fold compared with nonsmokers [7]. Lung 
cancer risk is not yet well-defined for inhalant drug use such as marijuana and 
cocaine; however research has identified similar molecular and histological 
aberrations indicating premalignancy of the lung tissue [7]. There are also other 
risk factors that have been attributed to the disease. Such factors include radon 
exposure, second-hand smoke exposure, carcinogen exposure such as asbestos 
and diesel gasoline exhaust fumes, prior radiation therapy, air pollution, 
carcinogenic chemicals such as arsenic in drinking water, and genetic mutations 
[6]. 
Although smoking accounts for the largest risk of lung cancer, nonsmoking 
and never smoking populations also presented with 20% of all lung cancer cases 
in 2018, suggesting other factors that may increase susceptibility in these 
populations [5]. Statistics reflect lung cancer deaths in nonsmokers continues to 
rise in rank and now presents as the 7th most lethal cancer in these individuals 
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and is thought to be attributable to secondhand smoke, environmental factors, 
and genetic driver mutations, as well as other factors previously mentioned [8].  
  
1.2 Lung Cancer Histological Classification and Therapeutic Implications 
 Lung cancer is divided into two broad categories: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer 
comprises 15% of all diagnosed lung cancer cases while its counterpart non-
small cell comprises the other 85% of diagnosed cases [7]. SCLC is considered 
to be a subtype characteristic of neuroendocrine differentiation, and is thus, 
classified differently than is NSCLC [9]. NSCLC can be further divided into three 
subcategories based on pathological differences: adenocarcinoma, squamous 
cell carcinoma, and large cell carcinoma [10]. Adenocarcinoma and squamous 
cell carcinoma combined account for over 70% of all cases, making them the two 
main subtypes [10]. Adenocarcinoma is the most common subtype of lung 
cancer overall, comprising 40% of all diagnosed cases and 60% of its NSCLC 
subtype [9]. Adenocarcinoma can present as either noninvasive (in situ) or 
invasive and is found along the periphery of the lung lobe, often superficially. 
Adenocarcinoma can be classified based on growth patterns as lepidic, meaning 
growing along alveolar structures; acinar, meaning growing in glandular patterns; 
papillary, meaning growing with the presence of “fibrovascular cores”; 
micropapillary, meaning growing in cellular “tufts” without the presence of a 
fibrovascular core; or solid, meaning growing in patternless sheets [9]. 
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Squamous cell carcinoma, on the other hand, presents in 20% of cases and is 
typically seen growing in a solid, nested pattern along major airways in the 
central portion of the lung lobe [9].  
 Over the past 20 years, advances have been made to more accurately 
identify molecular drivers of individual subtypes, allowing treatment plans to be 
specialized rather than treating subtypes as a singular disease. For example, 
epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain 
are of the most common driver mutations in NSCLC, occurring in approximately 
10% of all North American diagnosed cases [11]. Among the other common 
mutations are KRAS, occurring in about 15%-20% of NSCLC and 30%-50% of 
adenocarcinoma cases, receptor tyrosine kinase anaplastic lymphoma kinase 
(ALK), occurring in 3%-7% of NSCLC cases overall, and human epidermal 
growth factor receptor 2 (HER2), occurring in 2% of NSCLC cases, the majority 
of which are reported as adenocarcinoma [11].  
 
1.3 The Role of NNK in Lung Carcinogenesis 
 Tobacco smoke, already implicated as the leading risk factor in lung cancer 
incidence, has been thoroughly studied to understand the chemically-driven 
biological changes underlying tumorigenesis in lung epithelium. The key 
carcinogen responsible for lung tumorigenesis is nitrosamine 4-(methylnitro-
samino)-1-(3-pyridiyl)-1-butanone (NNK), also referred to as nicotine-derived 
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nitrosamine ketone [12]. The other major class of carcinogens proven to induce 
tumorigenesis discussed in the literature are polycyclic aromatic hydrocarbons 
(PAHs). However, nitrosamines have a more potent effect on carcinogenesis, 
producing a 100% success rate of inducing lung cancer in various rodent models 
[12, 13]. Studies have shown that NNK is a procarcinogen requiring metabolism 
through several cytochrome pigment 450 (CYP450) enzymes to convert it to the 
active forms 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and NNAL-
Gluc that are able to bind to DNA to form adducts [10]. Three such activation 
steps are required: 1. carbonyl reduction, 2. Pyridine N-oxidation, and 3. Α-
hydroxylation [12]. Once active, NNAL and NNAL-Gluc show affinity for DNA, can 
bind to and form DNA adducts, and induce DNA mutations if repair mechanisms 
are unsuccessful. This DNA damage ultimately leads to mutations in key 
oncogenes and tumor suppressor genes resulting in tumor initiation [14]. Several 
targets that are modulated by NNK to confer oncogenic activity are K-ras, Fas 
ligand (FasL), mitogen-activated protein kinase/extracellular signal-related kinase 
1 (MAPK/ERK1), proto-oncogene c-Myc, and B cell leukemia/lymphoma 2 (Bcl2), 
Cyclin D1 (CycD1), Nuclear Factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), and EGFR, among others [12]. 
 In addition to NNK’s roles in DNA mutation and alteration of oncotargets, 
NNK has also been shown to have immunomodulatory effects, altering immune 
targets such as interleukin-8 (IL-8), interleukin-6 (IL-6), monocyte 
chemoattractant protein 1 (MCP1), and prostaglandin E2 (PGE2) [12]. 
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 While NNK has been well-studied to have potent effects on lung tumor 
initiation, there are some published chemopreventive agents that have protective 
effects against NNK-induced tumorigenesis [12]. Deactivating known NNK-
stimulated oncogenes can provide an opportunity to intervene prior to 
tumorigenesis and progression. EGFR activation is a known effect of NNK 
exposure, and as such, targeting the pathway can prevent overly active 
proliferative effects [12]. Additionally, agents that can deactivate NNK-mediated 
phosphatidylinositol 3-kinase/ Protein Kinase B (PI3K/Akt) activation may also 
serve as viable chemoprevention strategies. Other targetable strategies include 
inhibition of CYP-mediated NNK conversion to active metabolites, activation of 
detoxification pathways, and increasing mechanisms to repair DNA damage from 
NNAL and NNAL-Gluc adduct formation [12]. For instance, some studies have 
shown β-estradiol can induce CYP450 enzymes to convert tobacco to active 
forms, making the estrogen pathway a targetable chemoprevention strategy [16]. 
 
1.4 Chemoprevention Status in Lung Cancer 
 Due to staggeringly high rates of lung cancer diagnoses and lung cancer-
related deaths annually, research to identify effective chemoprevention options 
has likewise, been propelled. Chemoprevention is defined as “the use of dietary 
or pharmaceutical interventions to slow or reverse the progression of pre-
malignancy to invasive cancer” and is becoming a useful strategy in other types 
of cancer [16]. The hallmarks of a successful chemopreventive agent include 
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delineating a high-risk population that is in need and identifying compounds that 
are both efficacious and have a favorable safety profile [16]. Lung cancer high-
risk individuals can be pinpointed via algorithms that mesh patients’ age and 
cumulative smoking history with known risk prediction models [17]. Despite the 
ability to ascertain patients at an increased risk of lung cancer, FDA-approved 
chemopreventive compounds are still lacking, despite a number of compounds 
that have undergone testing in preclinical and clinical stages [16]. Currently, 
smoking cessation is the only known factor capable of reducing lung cancer risk, 
and the risk of lung cancer still remains elevated in a former smoker than an 
individual with no smoking history with greater than half of diagnoses occurring in 
former smoker cohorts [16,18].  
 Chemopreventive intervention can be divided into 3 classes: primary, 
secondary, and tertiary [19]. Primary chemoprevention targets at-risk individuals 
who do not have a history of cancer diagnosis, whereas secondary can target 
individuals already exhibiting dysplastic lesions but that have not yet advanced 
into malignancy. Tertiary chemoprevention involves preventing neogenesis of a 
primary lesion in individuals who have a previously diagnosed pulmonary cancer 
[19].  
 A number of agents have progressed through preclinical testing into early 
phase clinical trials for lung cancer chemoprevention, but only 7 have entered 
phase III, and all without success [19]. Prior to entering phase III, phase II trial 
outcomes outline intermediate endpoints, that is, endpoints meant to predict the 
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overall objectives of a phase III trial which definitively measure reduced cancer 
incidence and morbidity [19]. Intermediate endpoints, for example, can include 
biomarkers effective of predicting response to a chemoprevention compound that 
results in a decrease in lung cancer incidence. However, to-date, no such 
biomarkers have been validated as accepted intermediate endpoints in lung 
cancer prevention [19]. Several suggested lung cancer chemoprevention agents 
that have undergone clinical trials address comorbid disease in high risk patients 
which could be advantageous to patients at high-risk of cancer. These patients 
often have other coinciding conditions to be managed like chronic obstructive 
pulmonary disease (COPD), pulmonary arterial hypertension (PAH), and 
diabetes mellitus (DM). Such chemoprevention agents have the potential to 
address premalignant risk as well as coinciding conditions: non-steroidal anti-
inflammatory drugs (NSAIDS), cyclooxygenase-2 (COX2) inhibitors, and 
prostacyclin analogs. [19, 20]. 
 Aspirin, a common over-the-counter NSAID, was tested in clinical trials, 
advancing to phase III testing, when prior preclinical testing found and 
association with aspirin use and decreased NSCLC incidence [21]. Phase III 
trials, however, failed to meet established endpoint of reduced conversion from 
Barrett’s metaplasia to adenocarcinoma [19, 22]. The phase III trial was 
conducted in a primary chemoprevention setting and all arms produced negative 
results [19].  
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 Celecoxib, a COX2 inhibitor, was tested in a phase II clinical trial after a 
plethora of preclinical evidence implicated the COX2/prostaglandin E2 (PGE2) 
pathway in lung carcinogenesis and indicated a potential opportunity for COX 
inhibitors in a lung cancer chemoprevention setting [23]. The primary 
intermediate endpoint assessed was the proliferative index marker Ki67, which 
was significantly decreased in accordance with reduction of lung nodules 
assessed through computed tomography (CT) scanning. However, not all 
patients experienced significant results with the drug, suggesting the need for 
further studies to elucidate a population of patients likely to receive the most 
benefit from this agent [23]. Furthermore, a subset of patients experienced 
adverse events related to toxicity, contraindicating safety which a major principle 
of chemoprevention agents [23]. Taken together, this data suggests progression 
towards viable lung cancer prevention options, but constitutes further 
investigation to find agents that meet all necessary benchmarks of an ideal 
chemoprevention agent.  
 Another recently investigated lung cancer prevention compound, iloprost, a 
synthetic prostacyclin analog that activates the prostaglandin pathway and 
peroxisome proliferator activated receptor gamma (PPARγ) pathway has shown 
some promising results in preclinical and early phase clinical testing. Prostacyclin 
is associated in normal lung tissue at high levels, whereas prostaglandin E2 
(PGE2) is found to be at high levels in lung tumor cells [24]. Furthermore, 
elevating prostacyclin by genetic or pharmacological means results in lung 
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cancer prevention in murine models [23]. A phase II trial of oral iloprost was 
conducted to evaluate biopsy score change over a 6 month period of time [24]. 
Former smokers experienced a significant decrease of -0.39 compared to current 
smokers that experienced no difference in endobronchial dysplasia [24]. The lack 
of effect in the current smoker population reflects a common result in lung cancer 
chemoprevention studies, suggesting that smoking perpetuates pathways that 
cannot be negated by chemopreventive agents until active smoking ceases.  
 Retinoids make up the class of micronutrients falling under the umbrella of 
vitamin A derivatives. Retinoids have been well-studied and have published 
effects as chemopreventive agents [25]. However, there are also numerous 
instances in which it has negative or harmful effects [25]. In the context of lung 
cancer, a phase II clinical trial was conducted in a tertiary setting for patients with 
recurrent SCLC in which isotretinoin was used. In combination with interferon 
alpha (IFNα) and paclitaxel, the response in this study was 8.8% [25]. However, 
a phase III trial of isotretinoin for the prevention of lung cancer in current and 
former smokers was withdrawn due to increased mortality with the isotretinoin 
arm accounting for one third of the overall deaths in the study not attributed to 
lung cancer mortality [26]. Although retinoids may exhibit chemopreventive 
properties in lung cancer risk cohorts, it is clear that other compounds must be 
elucidated with improved safety profiles.  
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1.5 Sex Differences in Lung Cancer 
 Never smokers are defined as having smoked a total of 100 cigarettes or 
less in a lifetime as well as individuals who have been lifetime nonsmokers [7]. 
Prevalence of lung cancer in this cohort of individuals is about 15% of all lung 
cancer cases worldwide. When assessed by sex, 15% of worldwide lung cancer 
cases in men and 53% in women have no link to smoking history [7]. Although 
there is controversy regarding gender-specific susceptibility to the carcinogenicity 
of tobacco exposure, statistics remain clear delineating an increased female risk 
of mortality in nonsmoking lung cancer diagnoses compared to male risk [7]. 
Furthermore, women are more likely to develop both adenocarcinoma and small 
cell lung cancer while men are more likely to develop squamous cell carcinoma 
[13]. This large disparity raises questions on male versus female biological 
differences underlying lung cancer susceptibility and aggressiveness and 
strongly suggests a role of estrogen signaling in lung cancer [2].   
  
1.6  Estrogen Receptor (ER) Structural Biology, Activation, and Functions 
 The ER is a ligand-inducible intracellular transcription factor belonging to the 
nuclear hormone receptor (NHR) family and can be characterized into 2 different 
forms, estrogen receptor alpha (ERα, also ESR1) and estrogen receptor beta 
(ERβ, also ESR2) located on chromosome 6 and 14, respectively [27, 28]. ERα 
is primarily distributed in breast, ovary, and endometrial tissue, and ERβ is more 
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prevalent with primary tissue distribution in bone, brain, colon, endothelium, 
kidney, lung, ovary, prostate, and testes [28]. Both isoforms have the same 
structure, containing a transcriptional activation site (A/B domain), a DNA binding 
domain (DBD), a hinge-region, and a ligand binding domain (E/F domain) [28]. 
ERα and ERβ have 55% homology to one another in the ligand binding domain, 
and as such, have differing affinities for estrone and estriol, respectively. Splice 
variants within the ligand and DNA binding domains have been previously 
reported, as well [28].  
 Activated ER can mitigate its effects in several ways. In a genomic, nuclear 
fashion, ER will homodimerize with its ligand and can alter expression of target 
genes through DNA-interaction with cofactors and corepressors at site-specific 
areas of the DNA termed estrogen response elements (EREs) upon translocating 
to the nucleus [27, 29]. It is thought that transcriptional activity is mediated 
through activity of 2 domains called activation function (AF1 and AF2) domains 
located in the N-terminal and ligand binding domains [27]. ERα and ERβ have 
both been reported to bind and confer transcriptional effects through the ERE as 
well as through binding with other transcription factors such as activator protein 1 
(AP-1), stimulating protein 1 (Sp1), and NF-κB [27, 28, 29]. Additionally, ER can 
moderate signaling in a non-genomic manner, whereby 17β-estradiol (E2) binds 
ER and the ligand-receptor complex within the cell surface membrane can trans-
activate kinase pathways that mediate proliferation and survival pathways such 
13 
 
as MAPK/ERK1, PI3K/Akt, and EGFR as well as transcriptional regulation of 
target genes [28, 29].  
 
1.7 ERβ Signaling in Lung Cancer 
 As previously mentioned, ERα and ERβ have differing tissue distributions, 
and ERβ is the primary isoform located in the lung, whereas ERα has not been 
detected [28, 30].  ERβ murine knockout studies shed light on the biological 
function in the studies which includes alveoli formation and surfactant clearance. 
These mechanisms were found to be driven through transcriptional activation of 
ERβ target genes platelet-derived growth factor A (PDGF-A) and granulocyte-
macrophage colony-stimulating factor (GM-CSF). These postnatal lung 
modifications are described as sex-driven dimorphic characteristics controlled by 
estrogens in the lungs [30]. This sex-driven dichotomy, also present in increased 
lung cancer susceptibility in women, is not fully understood, but believed to be 
linked to estrogen [30].  
 Further study into this postulation revealed epidemiologic evidence pointing 
to a worse prognosis and more advanced disease in pre-menopausal women 
with functioning endogenous sources than post-menopausal women, all of whom 
were never smokers [15, 31]. Older, post-menopausal women also beat out male 
counterparts in showing a survival advantage [15]. Another study also found that 
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more, assumed pre-menopausal, women under age 50 were diagnosed with lung 
cancer than men of the same age range [32].  
 To this end, a hormonal link to lung cancer has been extensively studied. 
One such retrospective study conducted between 1984 and 1999 found that 
women who had used hormone replacement therapy had a lower median age of 
diagnosis by 5 years and decreased survival time by 40 months than women who 
had never taken hormone replacement therapies (HRTs) [33]. Another study 
conducted by the Women’s Health Initiative (WHI) reported a similar adverse 
effect on survival of women taking HRTs (estrogen plus progesterone) and a 
greater mortality risk to the HRT arm by 19% [15].  
 Although these sex differences in lung morphology and lung cancer exist, it 
is important to note that the lungs have been shown to be estrogen-dependent 
for normal morphology and estrogen-responsive in both males and females. ERβ 
knockout male and female mice experience alveolar collapse after 5 months of 
age, suggesting that functional estrogen receptor signaling is essential to both 
sexes. Furthermore, estrogen treatment caused reporter gene upregulation in 
both male and female mice ERE-luciferase reporter mice [34]. Additionally, 
human male tumor tissue contains similar expression amounts of ERβ to female 
tumor tissue, and human male-derived lung cancer cell lines are also estrogen-
responsive [35]. Both male and female-derived lung tumors also contain CYP19 
(aromatase) which is the rate-limiting enzyme necessary to convert androgen 
precursors into 17β-estradiol [35]. 
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 To further this understanding, studies on the functionality of the ER pathway 
in lungs utilizing a complete ER antagonist fulvestrant showed a blockade of 
tyrosine kinase signaling leading to decreased proliferation in lung tumor cell 
lines [34]. Estrogen has, likewise, gone on to show induction of proliferation in 
other studies using lung cancer cell lines, human cancer cell xenograft models, 
and murine lung cancer models [36, 37].  
 
1.8 Antiestrogens and Lung Cancer Prevention 
 Selective estrogen receptor modulators (SERMs) such as tamoxifen and 
aromatase inhibitors (AIs) such as anastrazole have shown both safety and 
efficacy in large clinical trials to prevent breast cancer that is hormone-
responsive. Tamoxifen in randomized trials conferred a decrease in both invasive 
and non-invasive breast cancer against the placebo groups by 50% [38]. As 
such, tamoxifen and raloxifen are now clinically prescribed for women at high-risk 
of breast cancer [39]. 
 With a solid basis of data suggesting estrogen blockade can combat lung 
cancer initiation and progression, research explored the realm of antiestrogens 
for use in lung cancer models. A population-based study in Taiwan found that of 
40,900 breast cancer patients taking antiestrogens (tamoxifen, raloxifen, 
toremifen, or AIs) as part of a therapy regimen experienced a significantly lower 
adjusted hazard ratio of 0.77 compared with nonusers [40].  
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 Preclinical studies have gone on to evaluate the safety and efficacy of 
antiestrogens in lung cancer chemoprevention. Stabile et al. assessed 
chemopreventive abilities of aromatase inhibitor anastrazole alone and in 
combination with estrogen antagonist fulvestrant in an NNK-induced murine lung 
carcinogenesis model. The combination conferred a significant decrease in mean 
number of tumor with the anastrazole and the combination with the greatest 
decrease seen with combination treatment. Along this trend, Ki67 expression 
was significantly reduced in all treatment groups, again with the largest reduction 
seen in the combination. In a similar model, anastrazole and fulvestrant exhibited 
decreased mean tumor size as well as decreased Ki67, however, the model 
assessed tumor advancement once hyperplastic lesions were established [41]. 
Fulvestrant has also been investigated in clinical trials in combination with other 
therapies for the treatment of advanced stages of NSCLC, owing to its efficacy in 
reducing proliferation of abnormal or malignant cells [42-45].  
 Finally, gene expression analysis of patients with advanced airway 
dysplasia revealed upregulation of upstream regulators linked to the estrogen 
signaling pathway as well as estrogen-responsive genes. A few of these 
identified pathways include transcription factor TBX2 implicated in breast cancer 
signaling, vascular endothelial growth factor (VEGF), hepatocyte growth factor 
(HGF), all of which are known to be induced by estrogen. Furthermore, 
progesterone receptor (PR) was found to be negatively regulated which is 
consistent with literature citing a loss of the PR pathway correlating to more 
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aggressive disease as well as a previously identified coupling of ERβ high/PR 
low tumors conferring negative prognosis in NSCLC. This preclinical evidence 
linking estrogen signaling with airway dysplasia persistence and progression 
creates further opportunity to implement antiestrogens in chemoprevention 
models, both alone and in combination with other agents. As previously 
mentioned, iloprost phase II clinical trial data as well as preclinical data from 
prostacyclin over-expression mouse model studies point to the utility of 
prostacyclins as chemopreventive agents in reducing lung tumor formation and 
found this in large part to be due to their activation of the peroxisome proliferator 
activated receptor gamma (PPARγ) pathway [46]. Promising preclinical and 
clinical results testing the repurposing of antiestrogens as well as other known 
tumor blunting pathways for use in at-risk and progressing lung cancer cases 
constitute further research to hone in on ideal populations of individuals most 
likely to benefit through identification of biomarkers when histological features 
cannot provide this insight.  
 
1.9 PPARγ Therapeutic Potential 
 Due to the dire state of lung cancer prognosis and survival rates, an 
imminent need for novel approaches to prevention and treatment drives research 
to investigate new targets. A natural progression towards investigation of agents 
capable of moderating smoldering inflammation leading to tumorigenesis has 
transpired after Hanahan and Weinberg established tumor-promoting 
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inflammation as a hallmark of cancer [47]. Among these agents are agonists of a 
potent anti-inflammatory and malignant growth inhibition pathway: the PPARγ 
pathway. PPARγ is a member of the nuclear hormone receptor superfamily and 
functions as a ligand-activated transcription factor most commonly known for 
driving transcription related to glucose homeostasis and adipocyte differentiation, 
thus its utility as a gold-standard target in anti-diabetic therapy [48]. Other known 
systemic roles outside of the utility of PPARγ in regulating metabolic processes 
include wound healing, inflammatory and immune modulation, angiogenesis, and 
augmentation of cellular processes including differentiation, proliferation and 
death [49, 50]. Discovery of these additional signaling effects has led to a 
plethora of preclinical research applying PPAR agonists in anti-cancer modalities. 
 
1.10 PPARγ Structure, Function, and Signaling 
 PPARγ falls into a receptor family containing 3 receptor isoforms: PPARα, 
PPARβ/δ, and PPARγ. The three isoforms are reported to retain 60-80% 
homology between each other in both the DNA-binding and ligand-binding 
domains [51]. PPARα has specificity in tissues with high metabolic activity such 
as heart, liver, kidney, and skeletal muscle while PPARβ/δ has diverse 
expression in most tissues with the most expression seen in the liver, kidney, 
adipose tissue, intestinal tissue, and skeletal muscle [50]. PPARγ has been 
described as the most well-studied PPAR isoform and is most abundantly found 
in adipose tissue but has also been reported to be expressed in many other 
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tissues such as liver, kidney, intestinal tissue, immune cells, and the lung [51, 
52]. PPARγ is further divided into two splice variants PPARγ1 and PPARγ2. Both 
isoforms have a similar amino acid sequence with PPARγ2 having 30 additional 
amino acids located at the N-terminal domain [53]. The structure of both PPARγ1 
and PPARγ2 contain a transcriptional activation site (A/B domain), a DNA-
binding domain (C domain), a hinge region (D domain), and a ligand-binding 
domain (E/F domain) [54].  
 Being a class of ligand-activated transcription factors, PPARs function by 
binding natural or synthetic ligands to agonize the receptor and allow release of 
co-repressors to facilitate binding of their counterpart, the retinoid-x receptor 
(RXR) to form a heterodimer. PPAR-RXR receptor heterodimerization then 
allows translocation to the nucleus to initiate mRNA transcriptional changes for 
PPAR target genes [51, 53]. This type of activation is PPARγ-dependent and 
confers the metabolic activity most-attributed to the pathway. PPARγ receptor-
independent activity is also reported with PPARγ agonists in which ligands can 
induce changes in kinase signaling pathways such as PI3K/Akt and MAPK 
resulting in augmented expression of growth factors, oncogenes, and cell cycle 
proteins to confer inhibition of cancer cell proliferation [53].  
 There are several reported natural ligands to the PPARγ receptor. These 
compounds relate to the metabolic regulatory capabilities of the PPARγ-
dependent processes and include certain fatty acids, eicosanoids, and some 
members of the family of low-density lipoproteins (LDLs). The most well-known 
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natural ligand reported to have the highest affinity to PPARγ of all the known 
naturally occurring ligands is 15-deoxy-∆-12-14-prostaglandin J2 (15d-PGJ2) [49]. 
Although 15d-PGJ2 is the endogenous ligand with most affinity for PPARγ, overall 
potency is low for naturally occurring ligands. As such, a class of synthetic 
PPARγ ligands known as thiazolidinediones (TZDs) were synthesized to have 
increased potency and specificity for the receptor and are commonly used in 
diabetic therapeutic regimens due to their ability to sensitize cells to insulin [55]. 
The synthetic ligands in the class of TZDs on the market currently include 
pioglitazone, rosiglitazone, and lobeglitazone (approved for use in South Korea), 
but there are other analogs that have published uses in preclinical studies 
including two other well-known members ciglitazone and troglitazone. These 
synthetic ligands have been widely studied and are used commonly in the clinic. 
One retrospective human cohort study of 87,678 patients from Veterans Affairs 
medical centers, found those taking TZDs for diabetic purposes in comparison 
with nonusers experienced a 33% reduction in lung cancer incidence [56]. 
Further preclinical investigation into PPARγ-independent mechanism of action 
relating to cell cycle, cellular proliferation, and inflammatory modulation in an 
anti-neoplastic context revealed its function in pathways that drive tumor 
suppression in several malignancies including lung cancer [48]. 
 One such function identified as a downstream effect of PPARγ activation is 
terminal differentiation. Several NSCLC lineages have reported upregulation in 
pro-differentiation proteins such as surfactant protein A (SP-A) and gelsolin. 
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A549 cells, one such NSCLC line, have been shown to sustain extracellular 
signal-regulated kinase 1/2 (ERK1/2) activation as a result of PPARγ activation 
with an agonist [48]. In addition, studies have shown that activated PPARγ 
signaling in several human cancer cell lines induces cell cycle arrest, apoptosis, 
and in some cases, re-differentiation [57-60].  
 PPARγ has been extensively shown to regulate inflammation as an 
additional means of regulating the TME in cancer. One such study revealed that 
inhibition of PPARγ signaling in myeloid cells led to abnormal immune cell 
populations, expansion of myeloid-derived suppressor cell (MDSC) populations, 
reduced T-cell populations, and therefore, immunosuppression all contributing to 
tumorigenesis. Furthermore, a lack of PPARγ signaling depleted pro-
inflammatory gene expression in MDSC populations [61].  
 Current findings summarize the effects of PPARγ activation on lung cancer 
to be cell context-dependent, resulting in a multitude of varying effects based on 
the cell type in question within the tumor microenvironment. Juxtaposing the 
aforementioned effects of PPARγ activation conferring an anti-tumor message in 
epithelial and other tumor microenvironment (TME) supporting cells, some 
current research exposes evidence linking PPARγ activation in certain myeloid 
cells with pro-tumorigenic functions. One such study found that systemically 
activating PPARγ in a syngeneic mouse model of lung cancer did not confer the 
expected tumor regression, but rather resulted in increased brain and liver 
metastases [62]. Upon further investigation, it was discovered that PPARγ 
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activation in tumor associated macrophages resulted in an increased Arginase-
1+ population which is well-characterized to have pro-tumorigenic functions. 
Based on the results of this study, it is clear that understanding the dynamic 
between PPARγ activation and tumor-associated macrophage populations will 
prove essential in creating the most efficacious PPARγ-centric therapeutic 
modality.  
 However, conflicting evidence from a study using dominant negative PPARγ 
(dnPPARγ), a mutant PPARγ receptor capable of silencing activation of the wild-
type receptor, indicates that an inhibition of PPARγ activity results in an 
overwhelming pro-inflammatory response with a cascade of negative effects 
including activation of myeloid-derived suppressor cell (MDSC) populations 
resulting in depletion of T-cell subsets, induction of proliferation and pro-survival 
pathways, and induction of metastasis [63].  
 Although mounting evidence underpinning the complex role of PPARγ 
activation in tumor progression leaves more questions than answers, it is clear 
that PPARγ is a key player in tipping the scale of the TME towards or against 
tumorigenesis. Furthermore, studies aimed at understanding the effects of 
combining thiazolidinediones with other anti-cancer modalities will not only 
advance knowledge of PPARγ mechanism of action in cancer, but also provide 
promising novel solutions to the growing need for newer, inventive therapy 
options. 
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1.11 PPARγ Clinical Significance in Lung Cancer 
 Due to the anti-neoplastic capabilities of agonizing the PPARγ pathway, 
preclinical support of its effects has begun to transition into clinical studies to 
elucidate its chemotherapeutic and chemopreventive potential in humans. Only a 
few clinical trials are reported using pioglitazone in the context of lung cancer 
therapy. One study, although it contained few participants, did cite reductions in 
post-treatment expression of Ki67, CycD1, and cell cycle protein p21. 
Furthermore, the study reported no serious adverse effects, suggesting that 
further studies be conducted with increased accrual to elucidate 
chemotherapeutic potential of TZDs in lung cancer [64]. Another study, 
conducted in a chemoprevention context using pioglitazone, aims to uncover 
potential utility of this agent in a safe and effective manner [65]. Further studies 
can help direct the use of this medication to benefit individuals at risk of 
developing lung cancer. 
 
1.12 Pioglitazone Risk Factors 
 It is widely accepted that individuals with diabetes carry a higher risk of 
bladder cancer [66, 67, 68]. However, research varies on whether or not that risk 
can be positively associated with medications used to treat diabetes such as 
TZDs and angiotensin receptor blockers (ARBs). Several cohort studies have 
been performed in order to stratify this risk particularly pertaining to TZD use, and 
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yet, the results are widely varied. Both prevalent and incident-based statistics on 
pioglitazone use were analyzed in a Medicare cohort population during the years 
2003-2011. There was a 16% risk associated with pioglitazone use in a 
prevalence context and no associated risk identified in the incidence cohort [66]. 
A meta-analysis collecting data dating to July 2013 of 5 randomized-controlled 
trials (RCTs) and 13 observational studies also identified an increased risk of 
bladder cancer with pioglitazone use with odds ratios of 2.51 and 1.21 in the RCT 
group and observational study group, respectively [69]. However, another meta-
analysis conducted between 2000-2016 compiled data from epidemiologic, 
controlled, and randomized studies identifying risk ratios of pioglitazone use and 
bladder cancer occurrence and found no significant difference in hazard ratio 
(HR) between pioglitazone users and nonusers [67]. Several other studies 
conclude similar confounding results [70, 71]. Due to the inconsistency of results 
from these large studies, further stratification of factors such as age, sex, 
countries of study, cumulative dose, duration of dose, and other confounding 
medical factors that may potentiate the risk of bladder malignancy associated 
with TZD use is needed to properly distinguish increased risk populations. 
 
1.13 PPARγ and ER Cross Talk 
 A paper published in 2014 by Chu et al. outlined a reciprocal regulation of 
PPARγ and both ERα and ERβ. It was found that overexpression of either 
receptor led to the repression of protein level and activity of the other, and 
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conversely, knockdown of either receptor with siRNAs led to an increase in 
expression of the opposite receptor. Treatment of the thyroid carcinoma cells 
with PPARγ agonist rosiglitazone reduced ERβ expression. In reciprocal fashion, 
ERβ agonist diarylpropiolnitrile (DPN) also reduced PPARγ expression. 
Furthermore, they observed that this novel interaction between PPARγ and ERβ 
were able to sensitize thyroid carcinoma cells to expression of pro-apoptotic 
molecules and reduced proliferative and migratory activity of the thyroid cancer 
cells [72].  
 Other studies have found links between the PPARγ and ER pathways, most 
of which are in reproductive or hormone-driven tissues. In an in vitro model of 
endometriosis, ciglitazone was found not only to reduce cell cycle proteins and 
increase apoptotic pathways, but also to decrease expression of aromatase and 
subsequent estrone production in the endometriotic cells, further supporting 
evidence of PPARγ/ER cross-talk [73].  
 A study in breast cancer MDA-MB-231 and MCF-7 cells found a similar 
bidirectional interaction between the two receptors. This was demonstrated, in 
part, through ER activation with expression vectors and measurement of 
subsequent peroxisome-proliferator response element (PPRE) reporter 
transcriptional activation with a Luciferase construct. ER activation conferred a 
decrease in reporter activity, and similarly, PPARγ activation increased reporter 
activity, and addition of ER expression vectors blunted this effect [74]. To this 
end, another paper published using MCF-7 and HeLa cells demonstrated for the 
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first time that a possible direct interaction between ERα and PPARγ exists. The 
study showed through coimmunoprecipitation that the two receptors are bound. 
Furthermore, they demonstrated that ERα can mediate its effects on the PPARγ 
signaling pathway by binding to the PPRE and suppressing transactivation [75]. 
Several other articles have shown a similar bidirectional interaction between 
PPARγ and ER; however, fewer have elucidated the role of ERβ, specifically, as 
opposed to ERα in this interaction and to-date, studies aimed at understanding 
this receptor interplay in lung cancer are lacking. Increased therapeutic benefit is 
possible with a heightened understanding of the communication between PPARγ 
and ERβ in lung cancer, allowing for inventive therapeutic combinations of new 
and existing agents.  
 
 1.14 Macrophages in Cancer 
 Macrophages provide necessary function in many normal physiological 
processes including mounting and resolving an immune response during 
infection, maintaining homeostatic balance in specific tissues, and wound healing 
following tissue damage. In addition to normal physiological functions, 
macrophages have also been implicated as initiators in tumorigenesis by 
sustaining inflammation associated with cancer risk and tumor initiation signals 
[76]. The infiltration of immune cells to the tumor microenvironment to promote 
tumor-specific inflammation is defined by Hanahan and Weinberg as one of the 
emerging hallmarks of cancer [77]. Of these immune cells, macrophages have 
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been identified as the main type of infiltrating leukocyte to the tumor bed to 
initiate tumor-promoting inflammation [78]. While these resident immune 
phagocytes can play normal, functional roles in organs such as the lungs, these 
infiltrating phagocytes are a noted player in tumor formation, progression, and 
metastasis [79]. This specific subset of macrophage has been given the term 
tumor-associated macrophages (TAMs) and their abundance in tissue is 
associated with poor prognosis in over 80% of published studies [80]. Like other 
subsets, TAMs are not fully understood, and studies have shown them to display 
both pro and anti-tumorigenic properties in a context-dependent manner [81]. A 
more complete understanding of TAM characterization in lung cancer will provide 
opportunity for therapeutic intervention in order to modulate macrophage support 
of tumorigenesis.  
  
1.15  Clinical Relevance of TAMs in Lung Cancer 
 Macrophages are a highly plastic myeloid immune cell as a result of their 
innate function to respond to immune signals and facilitate appropriate supportive 
responses in various tissue types. Resident alveolar macrophages in the lungs 
mount an appropriate immune response upon air entering the lungs into 
favorable or detrimental downstream effects as a consequence of the mixed 
stimuli the airway transports. Furthermore, epithelial and other stromal influences 
can exacerbate macrophage-driven effects to cause enduring inflammation 
preceding a variety of pulmonary disease states. Macrophages recruited to 
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preneoplastic and malignant lesions within the lungs create opportunity to 
continue spurring on this tumor-promoting inflammation and communicate with 
tumors to facilitate a favorable environment for growth and metastasis [82]. 
Although TAMs in lung cancer and their participation in cancer initiation and 
progression have yet to be well understood, lung cancer-specific studies are 
being conducted in order to elucidate correlative links between different subsets 
of TAMs and prolonged survival. The literature reflects varying conclusions 
regarding TAM phenotype and prognosis that is context-dependent based on 
stage and location [82].  A study recently published in 2019 found a link between 
“M1-like” TAMs, also known as pro-inflammatory activated TAMs, and enhanced 
survival and prognosis [83]. Tissue samples from NSCLC samples have also 
revealed that adenocarcinoma tissue areas have more CD68 and CD163 –
expressing macrophages than normal matched lung tissue [84]. A meta-analysis 
of lung cancer samples revealed that a higher rate of infiltrated TAMs correlated 
with worse overall survival (OS) and disease-free survival, and this association 
was likewise seen with the M2 population of TAMs, whereas the M1 population 
was associated with better survival [85].  
 
1.16  Macrophage Activation States 
 Macrophages have been described to exert juxtaposing functionalities due 
to their ability to exert either pro-inflammatory or anti-inflammatory effects in 
response to external stimuli. For instance, M1 or pro-inflammatory macrophages 
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promote inflammation through release of pro-inflammatory cytokines as well as 
antigen presentation and are characterized as being IL-10 low, IL-12 high, 
inducible nitric oxide synthase (iNos) high, and tumor necrosis factor alpha (TNF-
α) high [86]. M1 polarized macrophages through secretion of pro-inflammatory 
factors as well as reactive oxygen and nitrogen species confer immune 
responses to promote mounting immunity to destroy pathogens including tumors 
seen by the host immune system as foreign and detrimental to homeostasis [81]. 
Conversely, M2 or pro-tumorigenic macrophages facilitate the dampening of 
inflammation and wound-healing through release of anti-inflammatory and matrix 
remodeling cytokines and phagocytosis of debris. M2 macrophages are known to 
be characterized by Arginase1 (Arg1), IL-10, and mannose receptor c-type 1 
(Mrc1) (also known as CD206) among others [81, 86].  
 Previous notions on macrophage functionality outlined the M1 and M2 
dichotomy as black and white; however, extensive research on the functionality 
of these leukocytes supports a vast continuum of polarization states wherein 
these cells are plastic, subject to change fluidly with stimuli, and able to 
simultaneously express markers from more than one phenotypic category [87]. 
This plasticity is hypothesized to be highly complex in vivo due to the abundance 
of external varied stimuli that resident and recruited macrophages are subject to 
[88]. Moreover, recent research lacks a complete understanding of the vast 
immensity of macrophage phenotypes as a result of their plasticity [81]. 
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 Some literature suggests TAMs most closely resemble an alternatively 
activated M2 macrophage, exerting similar M2-like immunosuppressive functions 
related to promotion of cellular proliferation, angiogenesis, and resolution of 
inflammation [89, 90, 91].  This is thought to be due, at least in part, to a similar 
roster of cell-surface markers including CD163 and heat shock proteins [92]. 
However, there are other sources that have identified TAMs comprised of the 
traditional, M1/M2 dichotomy. Among many markers, a few identified to be potent 
and sensitive TAM markers are CD68, previously mentioned CD163, iNos, IL-1, 
VEGF, and Human Leukocyte Antigen – DR isotype (HLA-DR) [91]. These 
alternate subsets of TAMs work in opposing pro and anti-tumorigenic fashions to 
suppress or promote tumor growth, respectively [93].  
 
1.17 Effect of Estrogen Signaling on Macrophage Functionality 
 Estrogen plays a pivotal role in macrophage functionality and involvement in 
tumorigenesis and tumor progression. It has been found to modulate 
inflammatory signaling of TAMs implicated in hormone-driven cancers. Estrogen 
induces signaling of the transforming growth factor receptor beta (TGF-β) 
pathway which has potent immunosuppressive functions as well as shuts off pro-
inflammatory pathways IL-1 and TNF [94]. Furthermore, estrogen 
supplementation has shown to profoundly inhibit macrophage recruitment to 
areas of injury in a cardiovascular carotid artery disease in vivo model. The 
robust effect on chemotaxis was found to be mediated by monocyte 
31 
 
chemoattractant protein-1 (MCP1) also referred to as CCL2 [95]. Although 
research defining the role of estrogen and ER signaling on macrophage 
phenotype and functionality is scarce, there is evidence to support the role of ER 
signaling in alternative macrophage activation. ER knockout mice are resistant to 
IL-4-induced M2 differentiation, further supporting the evidence linking estrogen 
to an immunosuppressive microenvironment [95]. In addition to the direct effects 
on macrophage functionality and recruitment, estrogen was found to mediate T-
cell inhibition through antigen-presenting macrophages [95]. As such, SERMs 
and other agents involved in ER signaling ablation are being investigated as 
points of intervention to control estrogen-driven immune modulation leading to 
tumorigenesis [94].  
 
 
1.18 Effect of PPARγ Signaling on Macrophage Functionality 
 Owing to its dichotomy in pro and anti-tumorigenic effects, PPARγ activation 
although wholly identified as conveying anti-tumorigenic effects in a multitude of 
cells types, has also been implicated in tumor-promoting activities in certain 
stromal cells. PPARγ is widely expressed in stromal cells in the TME such as 
immune cell populations, endothelial cells, and fibroblasts [96]. Activation of 
PPARγ has been shown to vastly change the inflammatory landscape in a variety 
of disease states such as models of atherosclerosis and cancer. In the context of 
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cancer, TAMs have been implicated as a major population affected by this 
inflammatory shift with TZD administration. Several studies cite a shift towards 
TAMs with an anti-inflammatory, tumor-promoting phenotype with PPARγ 
activation [96, 97, 98]. Inflammatory pathways such as NF-κB are blunted, 
leading to downstream decreases in targets such as TNF, IL-1, and COX2 [99]. 
Shunting inflammatory responses away from pro-inflammatory pathways can 
lead TAMs to participate in pathways relating to angiogenesis, matrix remodeling, 
as well as other tumorigenic responses. As such, the cell context-dependent and 
time-sensitive manner in which PPARγ activation may affect the TME should be 
further investigated and thoroughly considered in order to maximize the benefit of 
PPARγ agonists with respect to chemotherapy and chemoprevention efforts.  
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2. Focus of Research 
 It is our overall hypothesis that activating the PPARγ pathway, an 
antineoplastic pathway in combination with inhibiting the pro-tumorigenic ER 
pathway is a more efficacious chemopreventive strategy than either approach 
individually in a chemoprevention model of NSCLC. We tested this hypothesis in 
two studies: 
I. Determining interactions between the PPARγ signaling pathway and the 
estrogen signaling pathway via in vitro modeling of macrophages and lung 
carcinoma cells simulating the tumor microenvironment 
II. Determining a potential enhanced effect between anti-estrogen fulvestrant 
and PPARγ agonist pioglitazone in reducing lung dysplasia and lung 
tumorigenesis in an animal model 
 
 
 
 
 
 
 
Model depicting the cycle of carcinogen induced adenocarcinoma, fueled by autocrine 
regulation of estrogen mediating smoldering inflammation via macrophages. 
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3. Materials and Methods 
Chemical Reagents 
Tobacco-specific NNK was purchased from TRC. Fulvestrant (ICI 
182,780) was purchased from Tocris Bioscience, and pioglitazone was 
purchased from Thermo Fisher Scientific.  
 
Cell Lines and Culture Conditions 
THP-1 immortalized human leukemia monocytic cell line was acquired 
from the Schwertfeger lab (University of Minnesota) and cultured in RPMI 1640 
medium (Gibco) supplemented with 10% heat-inactivated FBS, 1x 
penicillin/streptomycin (Thermo Fisher Scientific), and 1x GlutaMax (Life 
Technologies). A549 human immortalized NSCLC cell line was purchased from 
the American Type Culture Collection (ATCC) and was cultured in BME medium 
(Gibco) supplemented with 10% heat-inactivated FBS, 1x penicillin/streptomycin 
(Thermo Fisher Scientific), and 1x GlutaMax (Life Technologies).  Cell lines were 
authenticated by short tandem repeat DNA profiling and used within 6 months of 
testing. Frozen cell stocks were passaged a maximum of 15 times, and cells 
were mycoplasma-free. Cells were grown to 80-90% confluence in full serum 
medium incubated at growth conditions of 37°C and 5% CO2 prior to 
experimental setup.  
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Macrophage Individual Culture 
 THP-1 cells were seeded at 1.2E6 cells per well in a 6-well plate with 5 
ng/mL PMA in full serum RPMI 1640 growth medium. After 24 hour attachment, 
cells were serum-starved overnight approximately 18 hours with phenol red-free 
RPMI 1640 medium supplemented with 1x penicillin/streptomycin and 1x 
GlutaMax. Cells were subsequently left untreated as resting M0 state, or 
differentiated into M2 phenotype by supplementing the medium with 10 ng/mL IL-
4 (R&D Systems), 10 ng/mL IL-6 (R&D Systems), and 10 ng/mL IL-13 (R&D 
Systems), respectively, for 24 hours. After 24 hour incubation for phenotype 
differentiation, THP-1 cells were treated with dimethyl sulfoxide (DMSO) (Thermo 
Fisher), 500 nM pioglitazone, 5 μM fulvestrant, and combination (500 nM 
pioglitazone and 5 μM fulvestrant), all at 1 uL per 1 mL of growth medium of 
DMSO for 24 and 48 hours prior to quantitative real-time PCR (RT-qPCR) and 
enzyme-linked immunosorbent assay (ELISA) of conditioned media endpoint 
analyses, respectively.  
 
Cancer Cell Individual Culture 
 A549 cells were seeded at 0.5E6 cells per well in a 6-well plate in full serum 
medium. After 24 hour attachment, cells were serum-starved overnight 
approximately 18 hours with phenol red-free MEM medium (Gibco) 
supplemented with 1x penicillin/streptomycin and 1x GlutaMax. Cells were 
36 
 
treated with DMSO, 500 nM pioglitazone, 5 μM fulvestrant, and combination (500 
nM pioglitazone and 5 μM fulvestrant), all in 1 uL per 1 mL medium of DMSO for 
48 hours prior to immunoblotting endpoint analysis. 
 
Cancer Cell Conditioned Media Co-culture 
 A549 cells were seeded at 0.5E6 cells per well in a 6-well plate in full serum 
BME medium. After 24 hour attachment, cells were serum-starved overnight 
(approximately 18 hours) with phenol red-free MEM medium supplemented with 
1x penicillin/streptomycin and 1x GlutaMax. Cells were treated with DMSO, 500 
nM pioglitazone, 5 μM fulvestrant, and combination (500 nM pioglitazone and 5 
μM fulvestrant), all in 1 uL per 1 mL medium of DMSO for 6 hours and medium 
was subsequently changed to fresh, serum free and incubated for 24 hours. 
Following 24 hour incubation, A549 conditioned media was placed on THP-1 
cells seeded according to the macrophage individual culture protocol and given 
24 hours to incubate prior to ELISA analysis of conditioned media. 
 
Macrophage/Cancer Cell Transwell Co-culture 
 THP-1 cells were seeded at 1.2E6 cells per well in a 6-well plate with 
5ng/mL PMA in full serum medium. After 24 hour attachment, cells were serum-
starved overnight (approximately 18 hours) with phenol red-free 1:1 RPMI 
1640:MEM medium supplemented with 1x penicillin/streptomycin and 1x 
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GlutaMax. Cells were subsequently left untreated as naïve M0 phenotype or 
differentiated into M2 phenotype by supplementing the medium with 10 ng/mL IL-
4 (R&D Systems), 10 ng/mL IL-6 (R&D Systems), and 10 ng/mL IL-13 (R&D 
Systems), respectively, for 6 hours and medium was subsequently changed to 
fresh, serum free and incubated for 24 hours. Following 24 hour incubation, 
polyethylene terephthalate (PET) transwell membrane inserts (Falcon) seeded 
with 0.5E6 A549 cells per membrane for 24 hours and then for approximately 24 
hours in serum-free 1:1 RPMI 1640:MEM medium were placed in wells with THP-
1 seeded macrophages and replaced with fresh medium for 48 hours prior to 
ELISA analysis of conditioned media. 
 
Isolation and Culture of Murine Bone Marrow-Derived Macrophages 
 After obtaining femurs and tibia from euthanized mice, bones were rinsed 
with ethanol followed by DMEM culture medium. Ends of bones were cut to 
expose the marrow and a 30mL syringe filled with DMEM culture medium was 
used to flush the marrow out of each bone into a 50mL conical tube. Bones were 
flushed from both cut ends to ensure maximum recovery of marrow. Once all 
bones were flushed, a single-cell suspension was made by drawing media 
containing the marrow back up into the syringe through the needle. Cells were 
centrifuged at 1200 rpm for 5 minutes at 4°C and supernatant was subsequently 
aspirated from the pellet. Pellet was resuspended in 3 mL ACK Lysis buffer (4.15 
g NH4Cl, 0.5 g KHCO3, 0.1 mM EDTA) for 1 minute and quenched with 10 mL 
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DMEM10 medium (DMEM growth medium supplemented with 10% FBS, 1x 
sodium pyruvate, 1x penicillin/streptomycin, and 1x GlutaMax). Cells were again 
centrifuged at 1200 rpm for 5 minutes at 4°C. Pellet was resuspended in 31 mL 
DMEM10 medium and cell count was performed, and 1E7 cells per dish were 
plated in 15 cm plates with a final volume of 30 mL of DMEM10 medium 
supplemented with 1x penicillin/streptomycin. On day 4 of culture, 15 mL of the 
medium was replaced with fresh medium. Cells were confluent and ready to be 
plated for experiments on day 6.  
 
Bone Marrow-Derived Macrophage Conditioned Media Co-culture 
 Bone marrow-derived macrophages (BMDMs) on day 6 are detached from 
culture plate with 0.25% Trypsin-EDTA (Gibco) for 5 minutes and quenched with 
culture medium, repeatedly pipetting the plate to ensure full detachment of cells. 
Cells were centrifuged at 1200 rpm for 5 minutes, and supernatant was 
aspirated. Cells were resuspended in medium, counted, and plated at a density 
of 1.3E6 cells per well in a 6-well dish and left as resting state or primed as M2 
with 10 ng/mL IL-4, 10 ng/mL IL-6, and 10 ng/mL IL-13. Concurrently, 3.5E5 cells 
per well of FVBW-17 cancer cells were plated in separate wells. After 24 hours of 
attachment, complete growth medium was removed and replaced with serum-
free DMEM and DMSO, pioglitazone, fulvestrant, and combination were added to 
BMDMs at previously specified doses. After 6 hour incubation of the drugs, 
medium was changed to fresh, serum-free and allowed to incubate for 24 hours. 
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After 24 hour incubation period, conditioned medium from BMDMs was placed on 
FVBW-17 wells. RNA was isolated from BMDM wells for future mRNA analysis 
and 0.5mL of conditioned media was reserved for ELISA analysis. After 24 hour 
incubation of BMDM conditioned media on the FVBW-17 cells, conditioned 
media was collected for ELISA analysis.  
Bone Marrow-Derived Macrophage Transwell Co-culture 
 Following previously described BMDM culture protocol, detached from 
culture plate with 0.25% Trypsin-EDTA for 5 minutes and quenched with culture 
medium, repeatedly pipetting the plate to ensure full detachment of cells. Cells 
were centrifuged at 1200 rpm for 5 minutes, and supernatant was aspirated. 
Cells were resuspended in medium, counted, and plated at a density of 1.3E6 
cells per well in a 6-well plate and left as resting state or primed as M2 with 10 
ng/mL IL-4, 10 ng/mL IL-6, and 10 ng/mL IL-13. FVBW-17 cells were plated in 
separate plates in transwell inserts at a density of 3.5E5 cells per membrane. 
After BMDMs were primed overnight for 18 hours, complete growth medium was 
removed and replaced with serum-free DMEM and DMSO, pioglitazone, 
fulvestrant, and combination for 6 hours, prior to replacing with fresh, serum-free 
medium and adding membrane inserts containing FVBW-17 cells. Transwell 
incubation proceeded for 24 hours prior to conditioned media collection for ELISA 
analysis and RNA isolation from BMDM wells for future mRNA analysis. 
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Anchorage-Independent Colony Formation Assay 
A549 NSCLC cells were detached from the plate using Trypsin-EDTA and 
seeded at a density of 1E4 cells per well in a 6-well plate in soft agar with full 
serum BME media to determine anchorage-independent growth. Sea Plaque 
Agarose (Lonza) was used to prepare 1.0% base agarose layer and a 0.75% 
upper agarose layer containing cells. After cell seeding in upper agarose layer, 
1mL of full serum BME growth media supplemented with DMSO, 500 nM 
pioglitazone, 5 μM fulvestrant, and combination (500 nM pioglitazone and 5 μM 
fulvestrant), all in 1 uL per 1 mL media of DMSO prior to incubation. Medium was 
replaced every 2-3 days, and colony formation was monitored after 14 days of 
treatment. Prior to colony visualization, media was aspirated and wells were 
incubated with crystal violet in 10% formalin for 1.5 hours. Using a dissecting 
scope, colonies were photographed in a 6-well plate (with 4 quadrants/well) using 
ImageJ software analysis to automatically count colonies, using 100 pixels as a 
cutoff with no circularity requirements. Large colonies were defined as 3,000-
infinity pixel units.  
 
 
 
 
 
41 
 
Protein Analysis 
Immunoblotting 
Following cell culture or lung isolation, cell or whole lung lysates were 
extracted and protein concentrations quantified using DC assay reagents 
(BioRad). Whole cell lysates (40 mg/sample) were electrophoresed on 7.5% 
SDS–polyacrylamide gels for 1.5 hours and transferred onto Trans-Blot 
polyvinylidene difluoride (PVDF) membranes (BioRad) for 1 hour at 100 volts on 
ice. The membranes were blocked using 5% nonfat dry milk and 0.1% Tween 20 
in 1x phosphate-buffered saline (TBST) for 1 hour. Membranes were incubated in 
primary antibody (in 1% milk in 1x TBS-Tween) at 4°C overnight and washed 3 
times with TBST at 15 minutes each followed by incubation with secondary host-
specific IgG antibody for 1 hour at room temperature (RT). After secondary 
antibody incubation, membranes were washed an additional 3 times in TBST at 
15 minutes each. Blots were developed using a super-enhanced 
chemiluminescence substrate according to the manufacturer's protocol (Thermo 
Fisher Scientific). Quantification of protein expression was assessed using 
ImageJ 1.X software (National Institute of Health, Bethesda, MD).  
 
Primary Antibodies 
Primary 
Antibody 
Host Dilution Manufacturer 
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Aromatase Rabbit 1:1000 Thermo Fisher 
COX2 Rabbit 1:2000 Cell Signaling 
Cyclin D1 Rabbit 1:1000 Cell Signaling 
ERβ Rabbit 1:1000 Thermo Fisher 
PPARγ Rabbit 1:1000 Abcam 
NF-κB Rabbit 1:2000 Cell Signaling 
pAkt Rabbit 1:1000 Cell Signaling 
pMAPK Rabbit 1:1000 Cell Signaling 
GAPDH Rabbit 1:1000 Cell Signaling 
 
Quantitative Real-Time PCR analysis 
Trizol (Invitrogen) was used to extract total RNA from cultured cells. One 
microgram of total RNA was reverse transcribed using a cDNA synthesis kit 
(Quanta Biosciences) using a T100 Thermal Cycler (BioRad). Real-time qPCR 
was performed using a SYBR Green Super Mix kit (Quanta) on a CFX connect 
Real-Time System (BioRad) according to manufacturer specifications. Gene-
specific primers for target genes were used to assess mRNA levels normalized to 
GAPDH mRNA levels as an internal control, and the ratio of normalized mRNA to 
the control conditions was determined using the comparative DCT method for 
analysis. The primers used for real-time qPCR are as follows:  
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Primers 
Target Forward Reverse 
GAPDH 5’-GGA GCG AGA TCC 
CTC CAA AAT-3’ 
5’-GGC TGT TGT CAT ACT 
TCT CAT GG-3’ 
Aromatase 5’-ACC CTT CTG CGT CGT 
GTC A-3’ 
5’-TCT GTG GAA ATC CTG 
CGT CTT-3’ 
CD209 5’-AAT GGC TGG AAC 
GAC GAC AAA-3’ 
5’-CAG GAG GCT GCG GAC 
TTT TT-3’ 
IL-23 5’-ATT TTC ACA GGG GAG 
CCT TC-3’ 
5’-GAC TGA GGC TTG GAA 
TCT GC-3’ 
Mouse IL-10 5’-CTG GAC AAC ATA CTG 
CTA ACC G-3’ 
5’-GGG CAT CAC TTC TAC 
CAG GTA A-3’ 
Mouse 
GAPDH 
5’-AAG GTC ATC CCA GAG 
CTG AA-3’ 
5’-CTG CTT CAC CAC CTT 
CTT GA-3’ 
 
Enzyme-Linked Immunosorbent Assay 
ELISA analysis was performed using either BALF isolated as previously 
described or conditioned-media isolated from individual or co-culture cell 
cultures. Host-specific kits were adjusted based on the source of medium being 
analyzed. Ligands were measured using commercially available ELISA kits from 
R&D systems. Each sample was run in triplicate to ensure accuracy and 
readings were normalized for total protein in each sample. 
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In vivo NNK-Induced Lung Carcinogenesis Model 
Timeline 
 All animal experiments were approved by Institutional Animal Care and Use 
guidelines. FVB/N mice were used for both intact and ovariectomized studies and 
were age and size matched. Mice were ovariectomized and delivered prior to 
study onset. Mice were given 3 mg of NNK intraperitoneally in sterile saline twice 
per week for a duration of 4 weeks, totaling 24 mg of NNK. Following carcinogen 
exposure, mice were given a 5 week rest period to simulate an ex-smoker 
population. Mice were then split into 4 treatment groups of DMSO in peanut oil 
vehicle (Thermo Fisher Scientific), 0.15% pioglitazone in medicated chow and 
DMSO in peanut oil vehicle twice per week, 30 mg/kg fulvestrant in peanut oil 
vehicle twice per week and control chow, and 0.15% pioglitazone in medicated 
chow plus 30 mg/kg fulvestrant in peanut oil twice per week. Peanut oil injections 
were given at a volume of 200 μL in the 14 week treatment groups for 
ovariectomized and intact models and for the 1 week intact treatment group. 
Vehicle oil volume was reduced to 100 μL for the 1,3, and 8 week ovariectomized 
treatment groups.  
Endpoints 
In 14 week-treated mice from both intact and ovariectomized studies, 
lungs were harvested and fixed in phosphate-buffered formalin, and 
subsequently transferred to 70% ethanol within 48 hours of formalin fixation. 
45 
 
Tumor burden of lungs was evaluated under a dissecting microscope for both 
tumor number and size. Tumors presented on the surface of the lung and were 
imaged and counted under a dissecting microscope. Images were then assessed 
for tumor size by measuring surface area using the LAS V4.12 Leica program. 
Lungs were further used for histological analysis via immunohistochemistry. 
 Bronchio-alveolar lavage fluid (BALF) was isolated from the lungs of 1, 3, 
and 8 week treated mice in both studies by flushing 1.5 mL of PBS through the 
bronchioles with a catheter and retracting all fluid to be saved for protein analysis 
and cells to be used for immunofluorescence. BALF was pooled by treatment 
group and saved on ice until all mice were euthanized. Samples were centrifuged 
at 1600 rpm for 5 minutes at 4°C and supernatant was saved for ELISA analysis 
at -80°C. Cell pellet was resuspended in PBS and cell count was performed. 
Cells were suspended at a final concentration of 1E5 cells per 300 μL PBS 
supplemented with 0.05% BSA. A Cytospin centrifuge was used to fix cells to 
slides at 1E5 cells per slide using a program set to run at 800 rpm for 3 minutes. 
Slides were fixed and dried overnight at RT and subsequently transferred to -
80°C for long-term storage until use.  
 
Lung Airway Histology and Immunohistochemistry 
Following formalin inflation and ethanol incubation as previously 
described, whole lungs were separated into individual lobes, cleaned of excess 
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connective tissue, and loaded into immunohistochemical cassettes for paraffin 
processing and embedding. A series of ethanol, Citrisolv, and paraffin 
incubations were performed for a total run time of 16 hours and 39 minutes. 
Tissue was then transferred to a beaker of paraffin and pressurized in a vacuum 
chamber for 30 minutes and subsequently embedded into paraffin using the 
immunohistochemical cassette. Blocks cured at 4°C overnight prior to sectioning. 
A microtome was used to section blocks at a depth of 5 mm per section, and 
tissue was fixed onto glass slides overnight at 37°C.  
For IHC staining, slides were deparaffinized and rehydrated using 3 
successive washes of xylene followed by ethanol ranging from 100% to 70%. 
Antigen retrieval was performed in a microwave oven for 20 minutes in a sodium 
citrate-based unmasking solution at pH6 followed by peroxidase blocking in 3% 
hydrogen peroxide for 15 minutes. The sections were incubated in host-specific 
blocking buffer (Vector Laboratories) for 1 hour at RT. Sections were then 
incubated with protein-specific primary antibodies and peroxidase-conjugated 
host-specific secondary antibodies. Sections were developed with DAB and 
counterstained with hematoxylin. Bright field microscopy was performed using 
Leica DM 4000B LED microscope, and images were captured at 20X and 40X 
magnification using LASv4.7 software. IHC analysis was performed blinded with 
15 images each from 5 mice per treatment group graded as low, moderate, or 
high. Staining was graded either as percent field or intensity-based. Percent-
based was graded as negative (0% positive staining), low (1-30% positive 
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staining), moderate (30-60% positive staining), or high (60%-100% positive 
staining). Intensity-based quantification was determined after ascertaining the 
range of intensity of positive staining found in all tissues for each protein of 
interest.  
 
Primary Antibodies 
Primary 
Antibody 
Host Dilution Manufacturer Catalog 
Number 
PPARγ Rabbit 1:800 Cell Signaling 2435S 
MMP9 Rabbit 1:1000 Abcam ab38898 
VEGF Rabbit 1:200 Abcam Ab52917 
F4/80 Rat 1:100 BioRad MCA497GA 
Cyclin D1 Rabbit 1:100 Abcam ab134175 
pAkt Rabbit 1:100 Cell Signaling 4060S 
AREG Rabbit 1:800 Invitrogen PA5-27298 
 
Flow Cytometry Analysis 
Whole Lung Digestion 
After mice were euthanized, lungs were suspended in RPMI 1640 medium 
supplemented with 10% FBS on ice. Lungs were subsequently incubated in 1x 
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collagenase (Sigma Aldrich) and 1x DNase I (Invitrogen) for 30 minutes in an 
incubator at 37°C with 5% CO2, with periodic mixing of the digestion buffer. After 
incubation, lungs were transferred to a strainer filter and mechanically pushed 
through the filter using the blunt end of 3 mL syringe, with periodic flushing of the 
membrane with RPMI medium. Cell count was performed and 1E7 cells were 
separated into sample tubes and brought to equal volume with FACs buffer (PBS 
supplemented with 2% FBS and 5 mM EDTA). Cells were washed once and 
incubated with Fc blocking antibody at 1 uL per 1 million cells for 15 minutes on 
ice. Cells were washed again and subsequently stained with fluorescently 
labeled antibodies using EFluor 506 live/dead dye (eBioscience), CD45 (BD 
Bioscience), CD11b (Biolegend), F4/80 (Biolegend), and CD206 (Biolegend) for 
30 minutes on ice in the dark. After incubation, cells were washed in FACs buffer 
and resuspended in FACs buffer supplemented with 0.5% paraformaldehyde 
(PFA) at a final volume of 0.5 mL. Fluorescently-labelled cells were analyzed and 
gated on an LSR Fortessa cell sorting machine, and data were further analyzed 
by FACsDiva. 
 
Statistical Analysis 
For statistical analyses, data were reported as mean ± SD or SEM. To 
assess significance between different treatment groups, a Student t test (two 
tailed) was used to determine significance with P values at least < 0.05 
categorized as statistically significant. To analyze IHC scoring data, the Chi-
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Squared test was used to compare the frequency of negative, low, moderate, 
and high scoring within and across treatment groups. Data represent biological 
triplicates with n=2 or n=3 per group per treatment group for all in vitro 
experiments.  
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4. Chapter I: Determining interactions between the PPARγ signaling 
pathway and the estrogen signaling pathway via in vitro modeling of 
macrophages and lung carcinoma cells simulating the tumor 
microenvironment. 
4.1 Introduction 
 Owing to its aggressive nature and current limitations on early detection, 
lung cancer, although not the most prevalently diagnosed form of cancer in the 
United States, is the most lethal, killing more individuals annually than the two 
most frequently diagnosed cancers, breast and prostate combined [1, 2]. As 
such, efforts to identify chemoprevention options to curb these statistics as well 
as novel chemotherapeutic options to target current therapeutic limitations in lung 
cancer are vital to reversing the dire state of the disease. Current approaches in 
chemoprevention aim to delay or prevent onset of malignancy and reeducate the 
tumor microenvironment in such a way to facilitate this delay through 
manipulation of pathways outlined in Hanahan and Weinberg’s widely accepted 
hallmarks of cancer [47].  
 ERβ cytoplasmic expression has been implicated as a negative prognostic 
indicator in lung cancer and has been shown to promote tumor growth and 
sustain tumorigenic inflammation, one such identified hallmark of cancer [47, 94, 
100]. ERβ, specifically, is the primary isoform in the lungs and is expressed 
equally in both male and female lung cancers [35, 41]. Anti-estrogens have 
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already been implemented for primary and secondary breast cancer prevention, 
showing excellent safety profiles for long-term use [101].  
 PPARγ was identified as a potentially efficacious chemoprevention agent 
following a cohort study identifying a decrease in lung cancer incidence in 
patients taking TZDs as indicated for type 2 diabetes mellitus [56]. A barrage of 
preclinical data supporting its anti-neoplastic effects was also elucidated [57, 59, 
61]. Furthermore, estrogen signaling was found to be upregulated in human lung 
dysplasias that positively regressed following a PPARγ agonism 
chemoprevention approach that were classified as persistent or aggressive at the 
onset of study [46]. Mouse models of lung cancer revealed that within the TME of 
these estrogen-sensitive lung cancers, an abundance of inflammatory cells 
positive for the estrogen synthesis enzyme aromatase as well as estradiol were 
identified, suggesting a local production and paracrine regulation of estrogen and 
ER signaling, supporting the exploration of anti-estrogens re-purposed for 
chemoprevention in lung cancer [41].  
 In this study, we tested the ability of a novel chemoprevention combination 
of PPARγ agonist pioglitazone and anti-estrogen fulvestrant to modify both the 
inflammatory environment via macrophages to decrease tumor-promoting 
pathways as well as the growth potential of cancer cells in vitro. Targeting two 
pathways known to be dually exploited in lung tumorigenesis could be a novel 
therapeutic niche to more effectively reeducate the TME against tumor-promoting 
effector signaling. To do this, we established a variety of co-culture models using 
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both human and murine macrophage and lung cancer cell lines to simulate 
cross-talk signaling occurring in the in vivo TME as a way to monitor the effect of 
pioglitazone and fulvestrant on macrophage functionality through inflammatory 
signaling pathways and cancer cell anchorage-independent growth. 
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4.2 Results 
Receptors and Downstream Targets are Present in Cell Lines 
 We first established the presence of both ERβ and PPARγ receptors (Figure 
1A) as well as several known downstream targets of both receptors in the human 
macrophage THP-1 cells (Figure 1B) and human NSCLC A549 cancer cells 
(Figure 1C). Cell lysates were analyzed via immunoblot analysis and probed for 
receptors and reported downstream targets. Both pioglitazone and fulvestrant 
single treatments upregulated expression of phosphorylated Akt and 
phosphorylated MAPK in THP-1 cells, both of which were alleviated with 
combination treatment (Figure 1B). Akt activation was not altered in A549 cells 
with treatments. Pioglitazone conferred a small decrease in MAPK activation 
which was not observed with combination (Figure 1C). 
 
 
 
 
 
 Figure 1. A. Immunoblot analysis of ERβ and PPARγ in both A549 NSCLC cells and 
THP-1 human macrophages. B. Immunoblot analysis of downstream ER and PPARγ 
protein targets in THP-1 macrophages after single and combination treatment for 24 
hours. C. Immunoblot analysis of downstream ER and PPARγ protein targets in A549 
NSCLC cells after single and combination treatment for 24 hours. 
A
B C
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M2 Macrophages Compared with M0 Macrophages Display Increased 
Sensitivity to ER Blockade 
 To understand how M2-polarized TAM-like macrophages differentially 
regulate estrogen production, real-time qPCR of mRNA isolated from naïve, M0 
THP-1 macrophages treated with PBS control and M2 THP-1 macrophages 
stimulated with IL4 and IL-13 confirmed by CD209 upregulation (p<0.001) 
revealed that M2 macrophages had approximately 2.5-fold significantly higher 
expression of aromatase, the rate-limiting enzyme that converts androgen 
precursors to estrogen, compared with the M0 counterpart (Figure 2A). This 
could suggest that M2 macrophages are more sensitive to estrogen signaling 
pathways as a feed-forward autocrine mechanism, as ER signaling has been 
reported to potentiate tumor-promoting immunosuppressive pathways in immune 
cells [94]. To test the functional effect of this upregulation in aromatase 
expression, M0 versus M2 macrophages were subject to an in vitro androgen 
precursor androstenedione (AD) and 17β-estradiol was measured in the 
supernatant via ELISA (Figure 2B). We observed a corresponding 2-fold increase 
in estradiol production that did not, however, reach statistical significance 
compared to M0 control.  
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Figure 2. A. Real-time qPCR analysis of aromatase expression of THP-1 mRNA in resting 
state PBS control macrophages or in IL-4 and IL-13 (IL-4/13) M2 macrophages primed for 
24 hours. B. Real-time qPCR analysis of CD209 expression of THP-1 mRNA in resting 
state PBS control macrophages or in IL-4 and IL-13 M2 macrophages primed for 24 hours. 
C. ELISA analysis of supernatant from resting state or M2-primed macrophages after 48 
hours incubation with estrogen precursor androstenedione (AD) compared to control wells 
without precursor. Data are expressed as mean + SEM. 
A. B. 
C. 
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Fulvestrant Causes a Paradoxical Upregulation of the ER Pathway in 
Macrophages 
 To determine the differential effect of drug treatments on estrogen 
regulation in M0 versus M2 macrophages, real-time qPCR of mRNA isolated 
from M0 or M2-stimulated THP-1 macrophages treated with DMSO control, 500 
nM pioglitazone, 5 μM fulvestrant, or combination treatment (500 nM pioglitazone 
and 5 μM fulvestrant) showed that fulvestrant increased aromatase 2-fold 
(p<0.05) in M0 macrophages and nearly 6-fold (p<0.0001) in M2-stimulated 
macrophages (Figure 3A), suggesting that similarly to results in Figure 2A, M2 
macrophages are more sensitive to pathways conferring anti-inflammatory 
effects such as the ER pathway, and that ER-blockade may further elevate this 
response. Combination treatment fully restored baseline aromatase expression in 
M0 macrophages and only partially rescued aromatase expression in the M2 
polarized cells. To measure the functional effect of differential aromatase 
expression across treatments, cells were subject to androstenedione and 
estrogen was measured via ELISA analysis of the supernatant (Figure 3B).  To 
functionally assess estrogen regulation in the M2-TAM population of 
macrophages in a TME-simulated culture, A549 NSLC cells were pre-cultured 
with DMSO control, 500 nM pioglitazone, 5 μM fulvestrant, or combination 
treatment (500 nM pioglitazone and 5 μM fulvestrant) and M2-polarized THP-1 
macrophages were exposed to conditioned media from the drug-treated cancer 
cells in the presence of androstenedione and estradiol production by the 
57 
 
macrophages was measured via ELISA (Figure 3C). Fulvestrant treatment 
conferred a significant increase in estradiol production compared to DMSO 
control. Although this increase did not reach significance, combination treatment 
was able to ablate the paradoxical increase by more than 2-fold (p<0.01) bringing 
estrogen below DMSO baseline. Similarly to treating macrophages directly with 
the drugs in Figure 3A, fulvestrant, likewise, stimulated the cancer cells to 
upregulate the ER pathway in M2-macrophages through paracrine signaling 
mechanisms and addition of pioglitazone was sufficient to significantly block this 
effect.  
 
 
 
 
 
 
 
 
Figure 3. A. Real-time qPCR analysis of aromatase expression of THP-1 mRNA in 
resting state PBS control macrophages treated with DMSO control, single, or 
combination treatments for 24 hours. B. Real-time qPCR analysis of aromatase 
expression of THP-1 mRNA in IL-4 and IL-13 M2-primed macrophages treated with 
DMSO control, single, or combination treatments for 24 hours. C. ELISA analysis of 
estradiol in supernatant from M2-primed macrophages that were challenged with 
conditioned media for 24 hours from A549 cells that were pre-treated with DMSO, 
single, or combination treatments for 6 hours. Data are expressed as mean + SEM.  
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Pioglitazone and Fulvestrant Combination Treatment Shifts Macrophages 
Away from a Tumor-Promoting Phenotype in Human Macrophage Cells  
 We then investigated the ability of pioglitazone and fulvestrant, both alone 
and in combination, to reeducate macrophages away from a TAM phenotype. To 
do this, we ran real-time qPCR of mRNA isolated from naïve, M0 or M2-
stimulated THP-1 macrophages treated with DMSO control, 500 nM pioglitazone, 
5 μM fulvestrant, or combination treatment (500 nM pioglitazone and 5 μM 
fulvestrant) to assess classic M1 markers iNOS and IL-23, alternative M2 marker 
CD209, and well-defined TAM markers CCL2 and MMP9. Naïve macrophages 
were educated by both single treatment and maximally by the combination to 
express higher levels of iNOS and IL-23 (Figure 4A). Furthermore, M0 
macrophages had lower expression of TAM markers CCL2 and MMP9, linked 
with macrophage chemotaxis propensity and matrix remodeling capability when 
treated with the combination (Figure 4C). Finally, in pre-educated M2 
macrophages, combination was able to regress expression of M2 marker CD209 
below DMSO control baseline expression, suggesting that the combination has 
the potential to revert already-established tumorigenic macrophages back to an 
inert state. (Figure 4B).  
 To more accurately confirm this potential regression of a TAM phenotype in 
a functional assay and elucidate the ability of the drugs to manipulate 
macrophage functionality in a paracrine fashion through cancer cells, we 
challenged the macrophages to the same TME-simulated culture as described in 
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Figure 3D where the A549 cells were cultured in the presence of the drugs and 
the cancer cell-conditioned media was then used to challenge M2-stimulated 
macrophages. We measured cytokines that have been previously reported to be 
secreted by TAMs to promote tumorigenesis. Pioglitazone, individually, does not 
alter VEGF levels, but fulvestrant single treatment is able to reduce secreted 
VEGF levels significantly (p<0.01) (Figure 5A). Combination showed the greatest 
decrease, surpassing the reduction seen with fulvestrant single treatment 
(p<0.001). This suggests that pioglitazone may confer its primary effect on VEGF 
synergistically through an estrogen-mediated pathway in macrophages to illicit 
maximal regulation of this well-defined mediator of angiogenesis. We also 
measured levels of IL-1β, a known inducer of COX2/PGE2 signaling which has 
also been reported to be negatively implicated in cancers [23]. Conversely to 
VEGF secretion, pioglitazone, alone, was sufficient to illicit maximal down-
modulation of IL-1β levels as a single treatment (p<0.01), suggesting that 
pioglitazone may work primarily to augment inflammatory pathways in the 
macrophages rather than pathways implicated in other tumorigenic activity 
(Figure 5B). Fulvestrant single treatment was able to reduce IL-1β, as well 
(p<0.05), although not to the degree that pioglitazone single treatment did. 
Furthermore, combination treatment maintained similarly reduced IL-1β secretion 
to pioglitazone single treatment (p<0.01), illustrating that combination does not 
have an additive effect on IL-1β secretion as it does on other targets.  
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Figure 4. A-B. Real-time qPCR analysis of expression of M1 markers iNOS and IL-23 
and TAM markers MMP9 and CCL2 in THP-1 mRNA in resting state PBS control 
macrophages treated with DMSO, single, or combination treatments for 24 hours. C. 
Real-time qPCR analysis of M2 marker CD209 expression in THP-1 mRNA in M2-
primed macrophages treated with DMSO, single, or combination treatments for 24 
hours. Data are expressed as mean + SEM.  
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Pioglitazone and Fulvestrant Combination Treatment Shifts Macrophages 
Away from a Tumor-Promoting Phenotype in Primary Murine Macrophages 
Figure 5. A-C. ELISA analyses of VEGF, IL-1β, and IL-10 in supernatant from M2-primed 
macrophages that were challenged with conditioned media for 24 hours from A549 cells 
that were pre-treated with DMSO, single, or combination treatments for 6 hours. Data are 
expressed as mean + SEM. 
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 We next aimed to investigate if the ability of single or combination 
treatments to reinstruct macrophages would translate to primary cells of murine 
origin. Primary murine macrophages were differentiated from bone-marrow-
derived monocytes and used in a resting state or primed as M2. After treating the 
macrophages with single or combination treatments, conditioned media from the 
macrophages was used to challenge FVBW-17 immortalized murine 
adenocarcinoma cells. We analyzed gene expression of the macrophages after 
subsequent drug treatments via real-time qPCR and analyzed secreted IL-1β 
expression by the cancer cells to determine the ability of pioglitazone and 
fulvestrant to modify macrophage function (Figure 6A-D) and subsequently, alter 
tumorigenic IL-1β cytokine production by the cancer cells (Figure 6E-F).  
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Figure 6. A. Real-time qPCR analysis of AREG expression of mRNA isolated from 
murine bone marrow-derived macrophages in resting state PBS control or in IL-4, IL-
6, and IL-13 M2 macrophages primed for 24 hours treated with DMSO control, 
single, or combination treatments for an additional 24 hours. B. Real-time qPCR 
analysis of VEGF expression of mRNA isolated from murine bone marrow-derived 
macrophages in resting state PBS control or in IL-4, IL-6, and IL-13 M2 macrophages 
primed for 6 hours treated with DMSO control, single, or combination treatments in a 
transwell model with FVBW-17 cells for an additional 24 hours. C-D. Real-time qPCR 
analysis of IL-10 and IL-1β expression of mRNA isolated from murine bone marrow-
derived macrophages (BMDMs) in IL-4, IL-6, and IL-13 M2 macrophages primed for 
24 hours then treated with DMSO control, single, or combination treatments for an 
additional 24 hours. E-F. ELISA analysis of secreted IL-1β in response to drug 
treatments of resting state  or M2-primed BMDMs, murine adenocarcinoma FVBW-
17 cells, and the change in IL-1β secretion of FVBW-17 cells in response to 
challenge of conditioned-media (CM) from drug-treated BMDMs. All cells were 
incubated for 24 hours with drug treatments or CM. Data are expressed as mean + 
SEM. 
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Pioglitazone and Fulvestrant Combination Treatment Alleviates 
Compensatory Signaling through EGFR and IL-1β 
 During our assessment of single versus combination treatments on 
pathways linked to inflammation and proliferation, we identified EGFR and IL-1β 
as two mechanisms by which pioglitazone and fulvestrant single treatments may 
attempt to overcome downstream effects of PPARγ and ER modulation. In order 
to assess the ability of combination treatment to rescue compensatory activation 
of these pathways, we analyzed EGFR ligand Amphiregulin (AREG) via ELISA in 
both a cancer cell conditioned media co-culture (Figure 7A) and transwell co-
culture (Figure 7B) models as previously described. A549 cancer cells under 
influence of fulvestrant, stimulated an increase in AREG production by M2-
primed THP-1 macrophages, which was significantly reduced by pioglitazone and 
fulvestrant combination treatment compared with DMSO baseline and with 
fulvestrant single treatment. This effect may be due to education of macrophages 
by the cancer cells to invigorate ER non-genomic signaling to cross-activate 
EGFR signaling as a means to compensate for loss of ER genomic signaling 
(Figure 7A). A similar trend was seen in conditioned media combining secreted 
protein from A549 and THP-1 macrophages, although in this model, combination 
treatment is only sufficient to revert AREG production back to the co-culture 
DMSO baseline. The baseline production of AREG in the DMSO control in Figure 
7A illustrates the propensity for A549 cancer cells to stimulate EGFR signaling 
when compared with AREG secretion in the THP-1 individual culture DMSO 
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control in Figure 7B. This suggests that paracrine signaling between 
macrophages and cancer cells elevates this compensatory pathway.  
 In Figure 7C, we analyzed secreted IL-1β via ELISA in the same transwell 
co-culture model described in 7B but with M2-primed macrophages. Similarly, 
fulvestrant elicited an upregulation of IL-1β secretion in THP-1 cells cultured 
alone; however, when the macrophages were combined with the cancer cells in 
the transwell system, pioglitazone single treatment exhibited the compensatory 
upregulation, whereas fulvestrant single treatment was able to significantly 
reduce IL-1β secretion, suggesting differential regulation of IL-1β in 
macrophages versus cancer cells or that paracrine interaction is necessary for 
fulvestrant to mediate its effects on the IL-1β pathway.  
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Figure 7. A. ELISA analysis of AREG in supernatant from M2-primed macrophages 
that were challenged with conditioned media for 24 hours from A549 cells that were 
pre-treated with DMSO, single, or combination treatments for 6 hours. B. ELISA 
analysis of AREG in supernatant from resting state THP-1 individual cultures 
challenged with drug treatments and transwell co-cultures of resting state THP-1 and 
A549 cells challenged with drug treatments for 48 hours prior to analysis. C. ELISA 
analysis of Il-1β in supernatant from M2-primed THP-1 individual cultures challenged 
with drug treatments and transwell co-cultures of M2-primed THP-1 and A549 cells 
challenged with drug treatments for 48 hours prior to analysis. Data are expressed as 
mean + SEM. 
C. 
A. B. 
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Combination Treatment Suppresses Colony Formation of A549 Cells in the 
Absence and Presence of THP-1 Macrophages 
 To assess the capability of single and combination treatment in reducing 
anchorage-independent colony formation of lung cancer cells, we cultured the 
A549 cells in agar alone (Figure 8A) or at a 1:1 ratio with the resting state THP-1 
macrophages (Figure 8B) in a soft agar plate. After DMSO, single, or 
combination treatment for a duration of 14 days, colonies were imaged and 
counted with ImageJ software. In the cancer cell individual culture, colonies were 
assessed in size categories gated by pixel units as small (1,000-2,000 pixel 
units), medium (2,000-3,000 pixel units), or large (3,000+ pixel units). In the 
cancer cell co-culture with macrophages, colonies presented in fewer quantity 
and resided below the 1,000-2,000 pixel unit gate previously mentioned, and as 
such, were quantified without size restrictions above a threshold of 184 pixel 
units in order to eliminate background debris and single cells. In the cancer cell 
individual culture, fulvestrant alone or in combination with pioglitazone confers a 
4-fold significant reduction in the quantity of large colonies formed (Figure 8A). In 
the cancer cell co-culture with macrophages, fulvestrant single treatment as well 
as combination treatment confer a significant 50% overall reduction in colony 
formation of all sizes (Figure 8B). 
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Figure 8. A. Representative images of colony formation of A549 cells cultured in soft 
agar across treatment groups (red arrow indicates a colony) and graphical 
representation of total number of large colonies (3,000+ pixel units) formed in DMSO 
control, single, or combination treatments. B. Representative images of colony 
formation of A549 cells cultured in a 1:1 ratio with THP-1 macrophages in soft agar 
across treatment groups and graphical representation of total number of colonies 
formed in each group above 184 pixel threshold. Data are expressed as mean + SEM. 
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4.3 Discussion 
 One identified mechanism of action for the anti-tumor effects of pioglitazone 
and fulvestrant in our postmenopausal lung cancer model is through the inhibition 
of stromal-derived aromatase and subsequent local estrogen production. In vitro 
analysis of macrophages shows a strong regulation of macrophage-driven 
estrogen production with combination, but not single treatments. Furthermore, 
this effect is magnified in an M2 macrophage population. Giles and colleagues 
were the first to describe aromatase expression as a particular feature of the M2, 
tumor-promoting macrophage phenotype within a breast cancer model [102]. To 
our knowledge, this is the first time these findings extend to the context of lung 
cancer and demonstrate that pioglitazone and fulvestrant are able to augment 
this upregulation to reduce the M2-driven estrogen feed-forward loop within the 
lung TME.  
 Our findings suggesting overcompensation of the ER pathway proceeding 
fulvestrant administration represents a recurring theme of resistance in single 
therapy approaches [103-106]. In an estrogen-dependent breast cancer model, 
Macedo and colleagues demonstrated a similar effect, whereby an intratumoral 
aromatase xenograft model displayed resistance to fulvestrant due to ER 
hypersensitivity conferred through increased ERα expression and aromatase 
activity [107]. This model was able to demonstrate the utility of fulvestrant in a 
combination approach to achieve enhanced reduction of xenograft tumor volume 
with aromatase inhibitor anastrazole. The ability to rescue fulvestrant-induced 
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estrogen hypersensitivity with the addition of pioglitazone presents a unique 
opportunity to purpose a known anti-tumorigenic agent in preclinical lung cancer 
models to rescue this hormone-dependent resistance mechanism in order to 
transition this combination application to be relevant in other hormone-driven 
models such as lung cancer.  
 Elucidating agents capable of educating the lung TME against the 
promotion of tumorigenic activities can be especially challenging, as some 
approaches in the repertoire of explored chemopreventive targets simply skew 
the dichotic switch from M2 to M1 phenotypic functionality. Potential pitfalls to 
these approaches lie in the reprogramming macrophages to a classically “M1” or 
pro-inflammatory primed state which is widely accepted to decrease tumorigenic 
stromal support; however, emerging evidence has shown that this approach may 
be oversimplified, as it can overlook certain pathways that are typically classified 
as pro-inflammatory, but actually have downstream activity that can promote 
tumor growth such as IL-1β [108]. Understanding the complexity of TAMs 
including their ability to manipulate both “M1” and “M2” signaling to facilitate pro-
tumorigenic activity is an important emerging concept in crafting agents capable 
of educating macrophages and other adaptive immune components to holistically 
promote anti-tumorigenic activity. Our novel chemoprevention approach 
combining pioglitazone and fulvestrant in macrophage and lung cancer TME 
models has shown efficacy in modulating both M1 and M2 cytokines to promote 
an overall anti-tumorigenic outcome. Maximum modulation of VEGF, IL-1β, IL-10, 
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AREG, and estradiol was achieved, signifying an important step forward in 
acknowledging and effectively modulating the heterogeneity of TAM signaling 
rather than the standard M1/M2 bipolar dichotomy. To our knowledge, this is the 
first data elucidating the inflammatory regulation of pioglitazone and fulvestrant in 
a combination approach and represents a promising foundation for future pre-
clinical study of this drug combination in lung cancer chemoprevention. 
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5. Chapter II: Determining a potential enhanced effect between anti-
estrogen fulvestrant and PPARγ agonist pioglitazone in reducing lung 
dysplasia and lung tumorigenesis in an animal model. 
5.1 Introduction 
 Efforts in chemoprevention of lung cancer are surging forward as a 
consequence of the high rate of diagnosis and dismal rate of survival. Despite 
ongoing advances in chemoprevention for other types of cancer, lung cancer is, 
to date, still lacking any FDA-approved options [16]. Sought after hallmarks of an 
ideal chemopreventive agent include a well-defined high-risk population in need 
of such therapy and utilizes compounds that are both efficacious to delay the 
onset of malignancy and have favorable safety profiles [16]. Smoldering 
inflammation, an emerging feature of malignant progression identified by 
Hanahan and Weinberg, has quickly become a target for chemoprevention 
efforts [47]. Several agents ascertained for lung cancer chemoprevention have 
surpassed preclinical testing, entered into early phase clinical trials, and 
advanced into phase III testing, only to be met without great success [19].  
 Often, patients that present in high-risk cohorts have comorbidities such as 
COPD, PAH, and diabetes mellitus that present their own set of risk factors and 
have the potential to contribute to the risk of lung cancer. Several agents have 
been explored to address these comorbid risks such as NSAIDS, COX2 
inhibitors, and prostacyclin analogs. [19, 20]. Within the NSAID category, aspirin 
held high promise for NSCLC chemoprevention after preclinical testing identified 
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a potential benefit [21]. However, phase III clinical trials failed to meet 
established endpoints or produced negative results [19]. Another inflammatory 
mediator identified as a potential beneficial agent in lung cancer prevention, 
celecoxib, works to block COX2. The agent, like aspirin, exhibited promise in 
preclinical models but failed to produce significant benefit in the majority of 
patients, and a subset of patients presented with toxicity, suggesting the need for 
further refinement of the cohort that can show clinical benefit without systemic 
toxicities [23]. 
 The PPARγ pathway represents another unique pathway being investigated 
in lung cancer prevention, and preclinical evidence implicates PPARγ in both 
anti-neoplastic as well as anti-inflammatory modalities [48, 51, 53]. The PPARγ 
agonist iloprost showed clinical benefit in reducing lung dysplasia in former 
smokers when tested in a phase II clinical trial. Former smokers experienced a 
significant decrease in endobronchial histology by -0.39 units compared to 
current smokers who experienced no difference in dysplasia [24]. In addition to 
clinical benefit seen by activating PPARγ, another major discovery from this 
study was the activated estrogen signaling gene signature present in dysplasias 
that were classified to be persistent/progressive [24]. Estrogen signaling has 
already been implicated as a driver of lung cancer, and antiestrogens have been 
implicated in murine models of lung cancer [41-45]. The selective estrogen 
receptor degrader fulvestrant has also been investigated in clinical trials in 
combination with other therapies for the treatment of advanced stages of 
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NSCLC, owing to its efficacy in reducing proliferation of abnormal or malignant 
cells [42-45]. Furthermore, in the context of chemoprevention, SERMs such as 
tamoxifen and aromatase inhibitors (AIs) such as anastrazole have shown both 
safety and efficacy in large clinical trials to prevent breast cancer that is 
hormone-responsive [38, 39]. Owing to this emerging data, combining a PPARγ 
agonist pioglitazone and an antiestrogen fulvestrant can provide a therapeutic 
niche to pinpoint two pathways known to be implicated in the onset of malignancy 
in lung cancer and may provide a novel approach to more efficaciously delay this 
progression to malignancy.  
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5.2 Results 
Receptors and a Representative Downstream Target are Present in the In 
Vivo Mouse Model 
 We first established the presence of both ERβ and PPARγ receptors (Figure 
9A) as well as COX2, a known downstream target of both receptors in whole lung 
tissue lysates isolated from the FVB/N mouse model with NNK exposure with 
MCF-7 breast cancer cells as a positive control. Study setup and timeline are 
shown in Figure 9B. 
 
 
 
 
 
 
 
 
 
 
 
A. 
Figure 9. A. Immunoblot analysis of whole lung protein lysates from NNK-
exposed FVB/N female mice and MCF-7 cell control. B. Murine study setup and 
timeline of NNK and drug exposure. 
B. 
FVB/N     MCF-7 
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Combination Treatment Significantly Reduces Tumor Burden in NNK-
Exposed Intact Female Mice 
 In order to define the efficacy of pioglitazone and fulvestrant, both singly and 
in combination, in a pre-menopausal model of lung cancer, we initiated 
adenocarcinoma formation with NNK in FVB/N mice and treated with placebo 
(DMSO control), single, or combination treatment for 14 weeks. After harvesting 
the lungs and assessing both tumor incidence and tumor size burden, defined as 
the sum of the surface area of all tumors in each mouse individually or across 
entire treatment group, we found that combination had reduced mean tumor 
incidence by 4.2 and reduced median tumor size by 0.6 mm2 (Figure 10A). 
Combination, but not single treatments, achieved significance in reduction of 
tumor size burden by 36% fewer tumors compared to placebo (p<0.01) (Figure 
10A) and a 2-fold reduction in average tumor size burden per mouse compared 
to placebo (Figure 10B). Average individual tumor size was found to be 
significantly smaller by 0.6 mm2 in combination treatment compared to placebo 
(p<0.05) depicted graphically (Figure 10C). Furthermore, assessment of 
individual tumor sizes observed across treatment groups were significantly 
different in combination treatment compared with pioglitazone single treatment 
(p<0.05) and fulvestrant single treatment (p<0.05) (Figure 10D). Finally, tumor 
incidence was found to be significantly less in pioglitazone single treatment 
(p<0.01) and combination treatment (p<0.001), both compared with placebo 
(Figure10E).  
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Figure 10. A. Table depicting 14-week intact treatment group study and major 
statistical results. B. Graph depicting group average tumor size per mouse (mm2). 
C. Graph depicting individual tumor sizes per mouse (mm2). D. Graph depicting 
tumor incidence per mouse across treatment groups. Data are represented as 
mean + SEM.  
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Whole Lung Lysate Protein Analysis from 1 and 14 week-Treated Lungs 
Indicates Individual Variation between Mice 
In order to assess the effect of pioglitazone and fulvestrant on 
downstream targets within the lung tissue, lungs from two mice harvested after 1 
week of treatment and 14 weeks of treatment were made into protein lysates and 
immunoblotting was performed to probe for several downstream targets of 
PPARγ and ER signaling. Variable expression of targets can be seen between 
treatment groups after 1 week of treatment (Figure 11A). There was not a clear 
trend seen towards modification of targets as we would have expected, but this 
could suggest that treatment effects may take longer than one week to alter 
protein expression in the lungs. After 14 weeks of treatment, COX2 and Cyclin 
D1 were down-modulated in the lung tissue of both representative mice from 
combination treatment, supporting our hypothesis that both pathways are 
downstream and subject to augmentation by both pathways (Figure 11B). We did 
not, however, observe a change in phosphorylated Akt as we expected (Figure 
11B).  
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A. 
B. 
Figure 11. A. Immunoblot analysis of whole lung protein lysates from 2 
representative NNK-exposed FVB/N female mice treated for 1 week in each 
group. B. Immunoblot analysis of whole lung protein lysates from 2 representative 
NNK-exposed FVB/N female mice treated for 14 weeks in each group. 
Quantification of protein expression was assessed using ImageJ 1.X software and 
changes are expressed below each lane. 
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Combination Treatment Alleviates Compensatory Estradiol Production in 
Single Treatment Groups in BALF of Intact Female Mice 
 We next assessed estradiol production in the BALF of 1, 3, and 14 week-
treated mice to determine if similar compensatory regulation of estrogen 
production with fulvestrant treatment was seen in vivo as it was in vitro. We 
observed an upregulation of estradiol production in both single treatment groups 
and the largest upregulation with combination treatment in the BALF of 3 week-
treated mice (Figure 12B). This could suggest that an early response to both 
single and combination treatments, which are working to block local lung 
estrogen signaling, potentially caused by a compensatory increase in aromatase, 
leading to more estrogen secretion as a means to overcome ER blockade. After 
just 1 week of treatment, estradiol levels are not significantly different in any 
treatment group compared with placebo (Figure 12A). However, compared with 
BALF from placebo-treated mice, BALF from a group of mice not exposed to 
NNK show over 2-fold significantly less pulmonary estradiol, supporting evidence 
linking estradiol to inflammatory pathways preceding tumorigenesis (Figure 12A). 
In contrast, estradiol levels are equivalent by week 14 across all groups (Figure 
12C). This suggests that the increase in estradiol over time seen in placebo 
represents a tumor-driven autocrine source of estrogen to continue to drive tumor 
progression at a late-stage time point.  
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Figure 12. A. ELISA analysis of estradiol production in the BALF of intact, female 
FVB/N mice subject to 1 week of treatment. B. ELISA analysis of estradiol 
production in the BALF of intact, female FVB/N mice subject to 14 weeks of 
treatment. Data are expressed as mean + SEM. 
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Single and Combination Treatments Significantly Reduce Tumor Burden in 
NNK-Exposed Ovariectomized Female Mice 
 Based on results showing a lack of efficacy on tumor size burden in single 
treatment groups and compensatory regulation of estradiol production in the 
BALF from the intact NNK mouse model, we hypothesized that the combination 
may display increased efficacy in a model without a reproductive source of 
estrogen. In order to assess the efficacy of pioglitazone and fulvestrant single 
and combined treatment on a post-menopausal model of lung cancer, we used 
the same experimental setup as shown in Figure 9B with female mice that were 
ovariectomized (OVX). After 14 weeks of treatment, tumor size and incidence 
were assessed similarly to the intact model (Figure 13A). Pioglitazone single 
treatment yielded a 28% reduction in overall group tumor size (p=0.9867) 
compared with placebo, fulvestrant yielded a reduction of 13% (p=0.2402) 
compared with placebo, and combination conferred a decrease of 51% 
(p=0.2601) when compared with placebo (Figure 13A). Median tumor number per 
animal was 2-fold lower in the combination treatment group compared with 
placebo (Figures 13A and 13E). Representative lung lobes from each treatment 
group in Figure 13B illustrate the main effect on reduction in tumor size seen in 
this study, and results representing average tumor size observed per mouse, all 
individual tumor sizes observed, and tumor incidence per mouse are reflected 
(Figures 13C and 13D).  
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Figure 13. A. Table representing major tumor burden results from 14 week-
treated ovariectomized female mice. B. Representative images of lung lobes 
containing tumors from 14 week-treated ovariectomized female mice. C. Graph 
depicting group average tumor size per mouse (mm2). D. Graph depicting 
individual tumor sizes per mouse (mm2). E. Graph depicting tumor incidence per 
mouse across treatment groups. Data are represented as mean + SEM.  
 
C. 
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Combination Treatment Alleviates Compensatory Estradiol Production in 
Pioglitazone Single Treatment Group in BALF of Ovarectomized Female 
Mice 
To assess whether compensatory estradiol regulation occurs when 
exogenous reproductive estrogen is removed from the system, we performed 
ELISA analysis on BALF from the 3 week-treated ovariectomized mice. In this 
model, we observed a significant decrease in estradiol in the fulvestrant-treated 
group, suggesting that ovariectomy was sufficient to prevent fulvestrant from 
increasing local estrogen production in the lungs (Figure 14) when compared 
with ELISA analysis of estradiol in BALF from the intact model (above). This 
result suggests that the effect of fulvestrant is dependent on an intact pituitary-
ovary reproductive axis, whereas the effect of pioglitazone likely affects the local 
tissue sources of estrogen irrespective of reproductive status. If PPARγ 
activation could potentially affect ER activity, which could lead to a slight increase 
in subsidiary estradiol levels if estradiol is incapable of binding the receptor. 
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Figure 14. ELISA analysis of estradiol production in the BALF of OVX, female 
FVB/N mice subject to 3 weeks of treatment. Data are expressed as mean + SEM. 
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Combination Treatment Significantly Down-Modulates Production of 
Secreted Factors in the BALF Involved in Mitigating a Pro-Tumorigenic 
Tumor Microenvironment 
 In order to assess the modulation of the pulmonary immune landscape 
across treatment groups, we analyzed secreted cytokines in BALF from 3-week 
treated mice in the OVX study via ELISA analyses. Pioglitazone treatment alone 
resulted in a significant decrease in EGF secretion (p<0.001). Both single and 
combination treatments were able to suppress EGF levels by 50%, although 
combination did not create added benefit (Figure 15C). IL-10 levels were 
maximally regulated by both fulvestrant (p<0.05) and combination treatment, and 
IL-1β levels reflected a similar trend (Figure 15A and 15B). Likewise, levels of 
AREG were maximally regulated by fulvestrant (p<0.0001) and combination was 
able to compensate for the increase seen in pioglitazone single treatment 
(p<0.0001) (Figure 15D). CCL2, a known regulator of macrophage chemotaxis, 
was also maximally down-regulated with fulvestrant single treatment (p<0.01) 
and combination treatment (p<0.001) (Figure 15E).  
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Figure 15. A. ELISA analysis of IL-10 production in the BALF of OVX, female 
FVB/N mice subject to 3 weeks of treatment. B. ELISA analysis of IL-1β production 
in the BALF of OVX, female FVB/N mice subject to 3 weeks of treatment. C. ELISA 
analysis of EGF production in the BALF of OVX, female FVB/N mice subject to 3 
weeks of treatment. D. ELISA analysis of AREG production in the BALF of OVX, 
female FVB/N mice subject to 3 weeks of treatment. E. ELISA analysis of CCL2 
production in the BALF of OVX, female FVB/N mice subject to 3 weeks of 
treatment. Data are expressed as mean + SEM. 
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Single and Combination Treatments Significantly Reduce Macrophage 
Burden in the Lungs of Ovariectomized Female Mice Treated for 8 Weeks 
and 14 Weeks 
As a secondary means of evaluating the inflammatory effect of 
pioglitazone and fulvestrant in the lungs, we analyzed the macrophage 
population within the lung tissue of 8 and 14 week-treated OVX mice. After 8 
weeks of treatment, we analyzed a single-cell suspension isolated from whole 
lung digestion of 4 mice per group via flow cytometry, and we observed that the 
primary CD45+ immune cell type present in the lungs were 
CD45+/CD11b+/F4/80+ macrophages depicted as population P6 within the dot 
plots. (Figures 16A-E). Furthermore, both single and combination treatments 
significantly reduce this macrophage population by 5% from the total immune cell 
population (Figure 16E). We also analyzed the effect of single and combination 
treatments on the CD45+/CD11b+/F4/80+/CD206+ macrophage population 
depicted as population P7 within the dot plots (Figures 16A-D and F). Here, we 
observed that both pioglitazone and fulvestrant single treatments increased the 
percent of M2 macrophages observed in the lungs after 8 weeks of treatment. 
Combination treatment alleviated the single-treatment effect on M2 macrophage 
burden back to placebo baseline (Figure 16F). Based on literature suggesting a 
role for pioglitazone in promoting M2 macrophage activation, we expected a 
potential single treatment effect on this population of M2 cells. Our hypothesis 
that the combination can alleviate negative effects on the promotion of M2 
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macrophage activation was supported, as we observed a decrease in CD206+ 
M2 macrophages with combination treatment (Figures 16D and F).  
We observed a large macrophage presence in the placebo group and a 
steady decline across treatments (Figure 17B). In order to assess potential 
differences in response to treatment within each treatment group, we split 
treatment groups into responder and non-responder populations, which consisted 
of mice with the smallest and largest tumor incidence and size burden, 
respectively. We hypothesized that a potential factor in a lacking response to 
treatments involved sustained macrophage presence in the TME. We found this 
hypothesis to be supported; each corresponding responder treatment group had 
a lower macrophage density than its non-responder counterpart (Figure 17B). 
Moreover, combination treatment groups, overall, displayed the lowest 
macrophage density compared with placebo or single treatments, suggesting 
roles of pioglitazone and fulvestrant in chemotaxis blockade of macrophages or 
corresponding chemokines, one of which could be CCL2 as previously identified 
(Figure 15E).  
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Figure 16. A-D. Dot plots representing percent events of CD45+ parent 
population positive for CD11b, F4/80, and CD206 macrophage markers in OVX 
mice subject to 8 weeks of treatment in A. Placebo B. Pioglitazone C. 
Fulvestrant D. Combination treatment groups. E. Graphical representation of the 
percent of CD45+ cells that are CD11b+/F4/80+ macrophages quantified across 
n=4 mice in each treatment group. F. Graphical representation of the percent of 
CD45+ cells that are CD11b+/F4/80+/CD206+ M2 macrophages quantified 
across n=4 mice in each treatment group. Data are represented as mean + 
SEM. 
A. B. 
C. D. 
E. F. 
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Figure 17. A. Representative images of F4/80 positive macrophages via 
immunohistochemistry of lung sections taken from NNK-exposed 14 week-treated 
OVX mice. B. Graphical representation of the total number of macrophages 
quantified across n=5 mice in each treatment group.  
A. B. 
93 
 
Combination and Single Treatments Modify PPARγ and Downstream 
Targets of PPARγ and ER Pathways in Lungs of 14 Week-Treated 
Ovariectomized Female Mice 
 In order to assess ER and PPARγ downstream signaling in vivo, we 
performed immunohistochemical analysis of a variety of targets both in 
preneoplastic lesions and tumor tissue from lungs of 14 week-treated mice in the 
OVX model. We wanted to analyze if maximal modulation of downstream 
signaling could be seen in early stage tumorigenesis as well as late stage. 
Protein targets analyzed were PPARγ (Figure 18), pAkt (Figure 19), Cyclin D1 
(Figure 20), VEGF (Figure 21), AREG (Figures 22-23), and MMP9 (Figures 24-
25).  
 PPARγ expression was measured in preneoplastic airways in responder 
and non-responder populations as previously described. As expected, we found 
that pioglitazone responder mice exhibited a significant induction of PPARγ 
compared with placebo (p<0.0001) (Figure 18). We saw an induction only in 
moderate staining in the pioglitazone non-responder cohort and a reduction of 
high staining when compared with placebo (p<0.0001). Pioglitazone responder 
and non-responder populations were significantly different from one another 
(p<0.0001), suggesting that regulation of PPARγ levels could be a contributing 
factor in response to treatment. Both fulvestrant responder (p<0.01) and non-
responder (p<0.0001) cohorts displayed a small induction of moderate, but not 
high PPARγ expression, suggesting that ER inhibition may have the ability to 
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alter PPARγ, although not to the extent of PPARγ agonism. A similar significant 
increase in moderate expression was seen in both combination treatment 
populations (p<0.01 and p<0.05). 
 Next, to assess anti-neoplastic activity of both treatments, we analyzed 
Akt survival signaling, a projected target of both PPARγ and ER signaling (Figure 
19). Neither single treatments nor combination treatment resulted in a significant 
reduction in Akt signaling within preneoplasias as we had expected. We 
hypothesized that combination would yield enhanced benefit in this pathway, but 
IHC of pAkt expression, although not statistically significant, appears to shift 
slightly towards increased high expression. 
 In order to assess the effect of pioglitazone and fulvestrant on a projected 
target of cell cycle regulation, we analyzed Cyclin D1 expression in tumor tissue 
to see if treatment effects are delineated in late-stage tumorigenesis versus 
early-stage neoplasia transformation (Figure 20). All treatment groups, 
regardless of response, did show an induction of negative and low expression, 
suggesting that pioglitazone and fulvestrant can induce pathways linked to cell 
cycle arrest. Furthermore, both single treatments and combination treatment 
were able to significantly reduce high expression of CycD1. Although we 
expected to see a shift towards lower expression pattern with combination 
treatment compared with single treatments, we observed an induction in high 
expression in the responder cohort of the combination treatment group, but we 
did not observe this effect in the non-responder cohort.  
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 We next wanted to compare tissue VEGF levels, both in preneoplastic 
airways (Figure 21) and in tumor tissue (Figure 22) after 14 weeks of treatment to 
VEGF regulation seen in the BALF from the 3 week early time point of study. In 
preneoplastic airways, VEGF expression was not significantly different between 
any treatment group and placebo, nor were there significant differences between 
responder and non-responder populations (Figure 21). However, VEGF 
expression in both response populations to pioglitazone single treatment 
displayed a decrease in moderate and high VEGF expression in tumor tissue 
(p<0.05 for both). Fulvestrant single treatment did not significantly alter VEGF 
expression. Combination treatment in the responder population, however, 
strongly induced VEGF moderate and high expression in tumors (p<0.01), and 
this response was reversed in the non-responder cohort (p<0.01), displaying an 
increased presence of low VEGF expression in tumor and a decrease in the 
abundance of moderate and high expression that was significantly different from 
the responder cohort (p<0.0001) (Figure 22). There was no low expression 
observed in this population, suggesting another potential rescue mechanism from 
anti-tumorigenic mechanisms likely amplified with combination treatment.  
 Based on previous data showing AREG-induced EGFR compensation 
with fulvestrant treatment, we wanted to confirm AREG expression in 
preneoplastic airways (Figure 23) as well as presence of AREG expression in the 
immune cell population of the lungs after 14 weeks of treatment (Figure 24). 
Similarly to previous data, AREG was shown to be induced in both single 
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treatment groups; however, unlike AREG secreted protein expression in the 
BALF after 3 weeks of treatment, combination treatment showed the largest 
induction of AREG expression by 14 weeks in the preneoplastic airways. This 
could suggest a stronger compensatory activation in response to anti-neoplastic 
effects of the combination seen after 14 weeks of treatment. This compensatory 
response appears to be sequestered to the epithelium, as the AREG-positive 
immune cell population decreases with both single and combination treatments 
(Figure 24).  
 Finally, in order to assess effects of pioglitazone and fulvestrant on 
invasive and metastatic potential of forming lesions, we measured MMP9 
expression of tumor tissue as well as MMP9-positive immune cell density after 
exposure to single and combination treatments for 14 weeks (Figures 25-26). 
Pioglitazone and fulvestrant single treatments confer a propensity of tumor tissue 
towards increased negative and low MMP9 expression, suggesting the ability of 
both treatments to affect the aggressiveness of the phenotype. However, 
combination treatment induces higher expression of MMP9, suggesting another 
potential compensatory mechanism to escape anti-tumorigenic treatment effects. 
A similar shift towards MMP9-high expression is seen in the tumor-infiltrated 
immune cell landscape (Figure 26) suggesting that pioglitazone and fulvestrant 
can affect matrix degradation and mobility of cancer cells through both direct and 
indirect mechanisms.  
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Figure 18. Immunohistochemical analysis of PPARγ expression in the 
preneoplastic airways of 14 week-treated OVX mice. Expression was quantified as 
intensity-based expression in fields with negative, low, moderate, and high 
intensity of positive staining. 
Figure 19. Immunohistochemical analysis of pAkt expression in the preneoplastic 
airways of 14 week-treated OVX mice. Expression was quantified as percentage of 
positive staining in preneoplastic airways with low (0-30%), moderate (30-60%), 
and high (60-100%).  
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Figure 20. Immunohistochemical analysis of Cyclin D1 expression in the tumors of 
14 week-treated OVX mice. Expression was quantified as intensity-based 
expression in fields with negative, low, moderate, and high intensity of positive 
staining. 
 
Figure 21. Immunohistochemical analysis of VEGF expression in the tumors of 14 
week-treated OVX mice. Expression was quantified as percentage of positive 
staining in fields with low (0-20%), moderate (20-50%), and high (50-100%).  
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Figure 22. Immunohistochemical analysis of AREG expression in the 
preneoplastic airways of 14 week-treated OVX mice. Expression was quantified as 
percentage of positive staining in preneoplastic airways with low (0-30%), 
moderate (30-60%), and high (60-100%).  
Figure 23. Graphical representation of the total number of immune cells staining 
positive for AREG quantified in random fields across n=5 mice in each treatment 
group.  
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Figure 24. Immunohistochemical analysis of MMP9 expression in the tumors of 14 
week-treated OVX mice. Expression was quantified as intensity-based expression 
in fields with negative, low, moderate, and high intensity of positive staining.  
Figure 25. Immunohistochemical analysis of tumor-infiltrated immune cells positive 
for MMP9 in the tumors of 14 week-treated OVX mice. Expression was quantified 
as number of positive staining cells in fields with low (0-10 cells), moderate (11-20 
cells), and high (>20 cells).  
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5.3 Discussion 
 An NNK-induced adenocarcinoma model of lung cancer in intact female 
mice represents an inclusive model of a population of at-risk individuals 
synonymous with pre-menopausal women with a history of smoking at an 
increased risk of developing lung cancer. Assessment of tumor burden from 
intact mice subject to 14 weeks of pioglitazone or fulvestrant single treatment did 
show a therapeutic benefit; however, single treatments did not reach statistical 
significance. Combination treatment resulted in a 44% decrease in tumor 
incidence compared with placebo and a 26% reduction in mean tumor size. 
Based on previously published results on pioglitazone and fulvestrant single 
treatment effects on lung tumor formation, we expected to achieve significant 
single treatment benefit as well as an added benefit with combination treatment. 
Previous studies using pioglitazone reported a significant decrease in tumor 
incidence in a benzo-α-pyrene model of lung cancer in A/J mice [109]. Another 
adenocarcinoma model utilizing pioglitazone found that it mitigated a maximum 
64% decrease in tumor load in a p53 wild-type vinyl carbamate-induced 
adenocarcinoma mouse model [110]. Furthermore, a previous study from our lab 
using fulvestrant in the ovariectomized NNK-induced adenocarcinoma model 
shown in this study cited a 44% decrease in tumor incidence and a 47% 
decrease in median tumor size burden [41]. Thus, this combination treatment 
model was expected to produce significance in single treatments and increased 
benefit in combination treatment with respect to tumor incidence and burden. 
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Pioglitazone has been reported to be most efficacious when given in the earliest 
stages of adenoma formation. It is possible that the potency to which NNK can 
induce adenoma formation in FVB/N NNK-susceptible mice allowed a more rapid 
adenoma formation than other carcinogen-induced models, and the timeline in 
which treatments began limited single treatment efficacy. Moreover, 
understanding that a major mechanism of action of fulvestrant relies on the 
competitive displacement of estradiol from the ER, it is plausible that circulating 
estradiol made by an intact reproductive system may displace kinetics that affect 
the ability of fulvestrant to effectively out-compete estradiol for the receptor. 
Therefore, it is possible that the lack of efficacy in fulvestrant single treatment 
may be, in part, due to an intact reproductive system, suggesting that this 
treatment modality may be most efficacious in a post-menopausal model of lung 
cancer. We can confirm that estrogen production was not adequately regulated in 
the intact model at any of the assessed endpoints in the BALF isolated from the 
lungs. As such, we opted to transition to an ovariectomized model for further 
testing.  
 The ovariectomized model was sufficient to mitigate a 50% decrease in 
tumor incidence with combination treatment compared with placebo, a 51% 
decrease in overall group tumor size with combination treatment, and a 13% and 
28% reduction in fulvestrant and pioglitazone single treatments, respectively. 
Estradiol assessment in BALF isolated from lungs after 3 weeks of treatment 
confirms that estrogen regulation is more efficaciously managed in the OVX 
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model when compared with that of the intact model. The increase in inhibition of 
tumor formation supports the earlier hypothesis that fulvestrant can more 
effectively compete for the ER. However, the observed reduction in tumor burden 
from both single and combination treatments was still not as sizable as the 
expected effect. It is possible that compensatory activation and 
overcompensation of target pathways downstream of both PPARγ and ER may 
be responsible for dampening the expected effect on tumor incidence and size 
burden.  
 Assessment of the early inflammatory response to pioglitazone and 
fulvestrant reveals a steady, decreased regulation of inflammatory and 
compensatory mediators of PPARγ and ER signaling with combination treatment 
such as IL-10, IL-1β, VEGF, and AREG. Furthermore, late-stage assessment of 
macrophage burden in the lungs after 14 weeks of treatment in the OVX model 
supports a role for the combination in modulating the inflammatory landscape 
away from a tumor-promoting TME. A strong, significant down-regulation of 
macrophage burden suggests than in addition to the roles of pioglitazone and 
fulvestrant in mediating inflammatory responses, they likely regulate presence of 
inflammatory cells through chemotaxis mechanisms like CCL2, as well. 
 However, late-stage assessment of similar TAM-like, pro-tumorigenic 
pathways points to steep compensation in combination treated mice. This 
suggests that combination can most effectively regulate these pathways, and as 
a result, proteins implicated in pathway signaling are being upregulated to 
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compensate for the loss. This effect was seen in several proteins involved in 
mitigating a pro-tumorigenic environment such as Akt, AREG, and MMP9 in 
tumor-infiltrated immune cells. As a result, due to the “rescue” phenotype seen in 
combination-treated mice after 14 weeks, it is reasonable to hypothesize that 
modulating other pathways in addition to PPARγ and ER can create added 
benefit in reducing lung tumor formation above that observed in this model in 
carcinogen-exposure models.  
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6. Discussion 
PPARγ and ERβ are known individually to be mediators of lung tumorigenesis 
and progression with downstream signaling pathways such as MAPK, Akt, Cyclin 
D1, and COX2/PGE2. Key roles for PPARγ in mediating tumorigenesis through 
survival, apoptosis, and terminal differentiation are well-defined and have been 
previously validated in cell culture and mouse models of lung cancer [58-61]. 
Likewise, ERβ plays a key role in regulating tumorigenesis, with known targets in 
proliferative and immunosuppressive pathways [34, 35, 37, 94, 100]. A phase II 
clinical trial of iloprost, a PPARγ activator, revealed a link between PPARγ-
responsive dysplasias that were phenotypically classified as aggressive which 
regressed with treatment and an activated ER signature, suggesting the potential 
for combined chemopreventive therapeutic benefit [46]. Additionally, both PPARγ 
and ERβ have been reported to interact in other models such as breast and 
thyroid cancer [72, 74, 75]. These targets, individually, are well-defined and 
present as prime targets for chemopreventive intervention. Prior 
chemoprevention agents that have targeted similar proliferative and inflammatory 
pathways had limited success in clinical trials either due to failure to meet 
established primary or secondary outcomes and confer therapeutic benefit, a 
poorly-defined biomarkers to predict a defined population likely to receive 
therapeutic benefit, or toxicity issues. An emerging hallmark of new-age 
chemoprevention strategies target at-risk populations for lung cancer that have 
comorbidities such as COPD and diabetes mellitus. Agents capable of 
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addressing comorbid risks for lung cancer initiation as well as underlying cellular 
mechanisms of tumorigenesis have the potential to increase therapeutic benefit. 
We have examined a novel therapeutic combination pioglitazone and fulvestrant 
that target the PPARγ and ER pathways. Pioglitazone is FDA-approved to treat 
type 2 diabetes mellitus as well as confers anti-neoplastic benefit in lung cancer 
models. Both pioglitazone and fulvestrant have established safety and efficacy 
profiles. The combination has not, to our knowledge, been studied in model 
systems of lung cancer. 
Here, we demonstrate that pioglitazone and fulvestrant have a robust 
chemopreventive effect on a mouse model of smoking-induced lung cancer. 
Treatment with the combination in vivo mitigated the growth of tumors by 40% 
compared with placebo. We predict that this effect on cell growth and 
proliferation slows or delays the growth of tumors based on in vitro analysis of 
treatments on anchorage-independent colony formation. Combination treatment 
mitigated a 55% decrease in anchorage-independent colony formation compared 
with placebo in culture alone and by 50% in large colony formation compared 
with placebo in co-culture with macrophages. We observed the slow growth of 
colonies over time in cell-culture rather than regression of established colony size 
with treatment, suggesting that pathways that mitigate the rate of growth such as 
cell cycle proteins like Cyclin D1 likely confer some of the therapeutic benefit 
seen with the combination.  
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We also hypothesized that the combination would mitigate 
immunosuppressive smoldering inflammation more effectively than either single 
treatment. A potential pitfall of agents that modulate the immune response of 
tumor and stromal cells emerges when agents implicated in chemopreventive 
intervention skew the dichotic switch away from M2-functional cytokines, 
chemokines, and growth factors and push M1-specific responses, some of which 
are involved in tumorigenic activity such as IL-1β [108]. Previously published 
studies cited therapeutic benefit of ER blockade in freeing immune-stimulatory 
pathways such as TNF and IL-1 that are blocked in the presence of functional 
estradiol signaling pathways as well as dampening estrogen-stimulated M2 
macrophage activation [94, 95]. Several studies cited a potentially deleterious 
effect of pioglitazone-drive macrophage TAM-like activation and functionality [96-
98]. We predicted that adding fulvestrant to pioglitazone could mediate this 
effect, as a published study in cardiovascular disease identified the need for a 
fully-functional ER signaling pathway to mitigate a full M2 response [95]. This 
study was able to validate this observation in the context of lung cancer TME 
model. Here, we showed that the combination more-effectively mitigated TAM-
functionality than single treatments both in the BALF of an NNK-induced lung 
carcinogenesis model as well as in co-culture modeling of the lung TME with 
human immortalized and murine primary macrophage and lung cancer cell lines. 
We have been able to demonstrate that the combination can maximally regulate 
pathways known to promote tumor initiation and progression including IL-1β, IL-
10, EGF, VEGF, AREG, MMP9, CCL2, and ER. We predict that one method of 
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rendering this inhibitory effect on smoldering inflammation is through the 
reduction in macrophage density with combination treatment. We hypothesize 
that decreased macrophage presence in the TME is likely through TME-mediated 
chemotaxis both in a paracrine fashion through cancer cells and other stromal 
components and autocrine fashion by the macrophages themselves based on 
decreased CCL2 expression both in macrophages and BALF from NNK-exposed 
mice receiving treatments. Taken together, we predict that pioglitazone and 
fulvestrant combined, unlike approaches taken in previously-tested 
chemopreventive strategies, can manipulate both classic M1 and M2 cytokines 
as well as proliferative and angiogenic pathways associated with tumor initiation 
and sustainment. This model signifies an important step forward in 
acknowledging and effectively modulating the heterogeneity of TAM signaling to 
precisely address the complexity of TAM regulation of the TME to more 
holistically promote anti-tumorigenic therapeutic benefit. 
We further hypothesized that the lungs are able to synthesize a local source 
of estrogen which can drive lung cancer formation and progression in an 
autocrine fashion based on models of the TME in breast cancer, TAM 
phenotyping in lung cancer, and preliminary data from previously published 
studies on mouse models of estrogen signaling in NNK-induced adenocarcinoma 
through assessment of ER pathway-compounds in TME immune cells. We 
identified autocrine production of estrogen in the in vitro models elucidating 
macrophage functionality. We also found estradiol production in BALF from NNK-
109 
 
exposed mice in the in vivo intact and ovariectomized studies. The presence of 
estradiol in the lung lavage from ovariectomized mice confirms a local source of 
estrogen production in the absence of a reproductive source of estrogen. 
Furthermore, we identified an increased sensitivity of M2, TAM-like macrophages 
to ER blockade compared with resting-state macrophages, suggesting that this 
pathway is key in mediating necessary TAM functions within that phenotype. 
Finally, we identified a hormone-dependent resistance mechanism similarly 
described in previous models of anti-estrogen use in other models of cancer, 
whereby estrogen-blockage causes an antiestrogen-induced estrogen 
hypersensitivity [103-106]. To our knowledge, this phenomenon has not yet been 
described in models of lung cancer. Furthermore, we show here that the addition 
of pioglitazone is sufficient to alleviate this compensatory regulation of estradiol 
production, creating a novel therapeutic benefit of this combination not previously 
described.  
We identified two other potential resistance-mechanisms to ERβ blockade 
and PPARγ activation. Single treatment of pioglitazone or fulvestrant in in vitro 
TME models with macrophages and NSCLC cells as well as BALF from in vivo 
studies showed a compensatory up-regulation of both the EGFR pathway 
through AREG and pro-tumorigenic and pro-angiogenic IL-1β. We predict these 
pathways are being turned on to rescue loss of positive proliferative signals and 
angiogenic signals by fulvestrant and pioglitazone. Combination treatment 
effectively ablates these compensatory increases both in vitro and in vivo, 
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representing a novel benefit of the combining both agents to more effectively 
mitigate rescue pathways.  
Despite ablation of rescue pathways seen in vitro and in early-stage 
tumorigenesis in vivo, we identified a potent rescue effect seen in preneoplastic 
airways and tumors during late-stage tumorigenesis after a 14-week treatment 
duration. Expression of Cyclin D1, a known downstream target of both PPARγ 
and ER, was reduced in both single treatments and with the combination 
compared with placebo tumors. However, the combination treatment group that 
displayed greatest response to treatment conferring the lowest overall tumor 
burden presented with more high tumor-expression of Cyclin D1 compared with 
single treatments or combination-treated mice less responsive to treatments. 
This suggests that proliferation and cell cycle is being decreased in these tumors, 
and as a result, Cyclin D1 is being upregulated to push to re-activate cell cycle 
progression. A similar phenomenon was observed in tumor-secreted VEGF, 
another target of both pathways suggesting enhanced regulation of angiogenesis 
by the combination. This effect was especially apparent in mice that were most 
responsive to combination treatment presenting with the lowest tumor incidence 
and size burden. We also observed this influence on AREG expression seen in 
preneoplastic airways as well as tumor-secreted MMP9 and tumor-infiltrating 
immune cells that were MMP9-positive, suggesting that this potent rescue-
phenotype is not limited to one downstream pathway, but is likely invigorated in 
pathways involved in both tumor-cell proliferation and the TME inflammatory 
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landscape downstream of PPARγ and ER and merits further study to elucidate 
treatment resistance mechanisms and biomarkers predictive of response to 
treatments. Taken together, our findings, to date, support the utility of combined 
pioglitazone and fulvestrant to mediate growth capacity of tumor cells and 
inflammatory mediation of the pulmonary TME to confer an overall 
chemopreventive benefit in a smoking-induced carcinogenesis model. These 
findings represent a promising foundation for future pre-clinical study of this drug 
combination in chemoprevention of lung cancer. 
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